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Introduction: Older adults have high prevalence of chronic illnesses that lead to have complex 
medication regimens. They are also more likely to have cognitive and functional impairments. 
Both cognitive/functional impairments and medication regimen complexity increase the risk of 
medication non-adherence. The objective of this study is to evaluate the association between 
prescription medication regimen complexity and cognitive/functional status at baseline and after 
two years, and to assess how changes in cognitive/functional status are associated with changes 
in medication regimen complexity.  
xiv 
 
Methods: This study used nationally representative sample of community-dwelling older adults 
from the Health and Retirement Study, followed over a two-year period. The exposures 
examined were cognitive status, and two types of functional status (Activities of Daily Living 
(ADLs) and Instrumental Activities of Daily Living (IADLs). The association between 
cognitive/functional status and medication regimen complexity was examined at baseline and 
after two years. Similar models were used to examine the relationship between 
cognitive/functional impairment and sub-components of complexity, and to assess how changes 
in cognitive/functional impairment were associated with changes in medication complexity over 
two years. 
Results: Impairment in ADLs were associated with higher medication complexity at baseline 
(p=0.0029) and after two years (p=0.0243). Impairments in IADLs were associated with higher 
regimen complexity at baseline only (p=0.0130). Stratifying by depression status, IADL 
impairment was found to predict higher complexity at both time points, but only in participants 
without depression. Cognitive impairment was associated with lower medication regimen 
complexity at baseline (p<0.0001) and after two years (p=0.0392). Changes in 
cognitive/functional status were not associated with change in medication complexity over two 
years. 
Conclusion:  ADL impairment was strongly associated with higher medication complexity. 
IADL impairment showed some association with higher medication complexity, but this 
relationship may vary according to depression status and requires further investigation. 
Recognition of these impairments may offer health care providers the opportunity to intervene by 
re-assessing medication regimens for patients with functional impairments. Cognitive 
impairment was associated with lower medication complexity. Changes in cognitive or 
xv 
 
functional were not associated with changes in complexity. Further study is needed to investigate 
this relationship over a longer period of time. 
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Chapter 1: Introduction 
 
1.1 Introduction 
Complex systems are prone to error, and where complexity exists the large number of 
interconnected elements increases the opportunity for errors to occur and that applies to 
medication regimens.1,2 With increases in the availability of prescription and non-prescription  
medication, medication regimen burden for patients has grown.2 Clinicians provide their care to 
the patient that has multiple comorbidities at a time when the development and the availability of 
medications has increased, which further complicates the medication regimen making complex 
medication regimens inevitable.3 
With increases in life expectancy and a growing range of medications available to treat 
chronic conditions, the use of prescription medications is likely to continue to increase as well,4 
particularly for community-dwelling older patients. These individuals constitute the largest 
group of consumers of prescription medication in the US, with approximately 20%  taking ten or 
more prescription medications.5,6 Current medical practice is largely based on guidelines, which 
help healthcare providers prescribe the right treatment for each condition. Although the use of 
guidelines helps reduce the risk of non-evidence-based prescribing, this increases the chances of 
putting patients with multiple conditions on a large number of medications chronically. Patients 
with multiple chronic diseases such as diabetes, hypertension, chronic obstructive pulmonary 
disease and depression are likely to be on several medications7,8 which is referred to as 
polypharmacy.9 The median number of medications prescribed to people aged 65 years or older 
doubled from 2 to 4 between 1988 and 2010. The proportion of older adults taking five or more 
medications has nearly tripled from 12.8% in 1988 to 39.0% in 2010.10  
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The increased use of medications is likely attributable to the concurrent increase in age-
associated chronic conditions.11 The estimated prevalence of having 2 or more 
chronic conditions is 64% among adults aged 65 to 74 years and 71% among those aged 75 years 
or older.12 The prevalence of functional impairment and cognitive impairment also increases 
with age.13 The aging process generally results in changes and reductions in functional ability, 
such as declines in physical fitness, flexibility, strength, endurance, and agility, resulting in 
difficulties preforming normal daily activities.14,15 As a result, the ability to function 
independently often declines with age. 
Age also plays a role in accelerating the development of neuronal dysfunction, neuronal 
loss, and cognitive decline, which contributes to multiple problems like decreased intellectual 
function and neurodegenerative diseases.16 In addition to age, older adults are often more likely 
to suffer from conditions such as heart disease, stroke, and arthritis that can lead to functional 
and/or cognitive decline.17,18,19 This is particularly concerning in light of the fact that functional 
and cognitive impairment are risk factors for difficulty adhering to a prescription medication 
regimen. Reductions in mobility may create difficulties in filling prescriptions; decline in 
functional ability to manipulate small objects may lead to difficulties opening prescription 
containers. These functional impairments can act as barriers to compliance with a prescription 
medication regimen.20,21 Furthermore, reduction in the ability to remember the details of the 
medication regimen can also contribute to non-adherence.22 Adherence to a therapeutic plan is 
vital for patients in order to get maximum benefits in the form of disease control and health 
maintenance. This is more important in the older adult population in which a large proportion 
living with chronic diseases resulting in polypharmacy. Poor adherence to medicines has 
negative effects on the individual. On a personal level, it results in delayed resolution of 
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illnesses, the worsening of the symptoms of the disease and can lead to an increase in healthcare 
costs. In United States, nonadherence is estimated to cost billions of dollars annually.23,24 
  Not taking medications at the correct time, missing doses, or not following other 
medication-related instructions could potentially result in the patient receiving a suboptimal 
clinical outcome and therefore lead to therapeutic failure.25 Poor patient compliance with 
medication regimens has been estimated to cause about 10% of hospital admissions in the United 
States.26 The World Health Organization (WHO) suggests that greater health benefits could be 
achieved by improving patient compliance with existing treatment regimens than by developing 
new medical treatments.27 Medication regimen complexity has been associated in previous 
studies with poor adherence to treatment, and was also identified by the WHO as one of the 
factors affecting adherence.25,28 Several studies have also shown that simplification of 
medication regimens can reduce non-adherence.25,29,30 Large numbers of medications, 
complicated medication schedules, or special instructions/requirements (such as cutting or 
breaking tablets or food interactions) can all contribute to medication regimen complexity and 
make it more difficult for patients to comply with the treatment plan.31,32 Complexity is one of 
the primary causes of patients’ non-adherence, with complex medication regimens reducing the 
likelihood of adherence to treatment.31 Therefore simplifications of medication regimens and 
greater attention to managing complexity are potential remediation strategies for poor adherence, 
and will be critical in helping patients to use their medications correctly.33 
1.2 Statement of the Problem 
Although medication regimen complexity and cognitive/functional impairments have 
both been associated with poor medication adherence, there is limited data on the relationship 
between cognitive/functional impairments and medication regimen complexity. One study by 
Herson et al. (2015) showed that independence in activities of daily living was inversely 
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associated with high regimen complexity.34 Study by Wimmer et al. (2015) showed no 
significant association between high medication regimen complexity and ADLs.  In this study 
and a study by Lee et al. (2012), the association between medication complexity and cognitive 
impairment was evaluated, and the results showed medication regimen complexity was lower in 
participants with cognitive impairment.35,36   
Further study of this relationship is needed, particularly in the United States population, as most 
of the existing studies were conducted in a non-United States population, which may have 
limited the generalizability. Furthermore, all existing studies were cross-sectional; there is a need 
for longitudinal studies, which may contribute new information to the understanding of this 
relationship. The proposed study will be the first to use a nationally representative sample of the 
United States older adult population to assess the relationship between medication regimen 
complexity and cognitive/functional impairments using a longitudinal design. 
1.3 Research Questions and Hypotheses 
Research Question: Is there an association between the functional/cognitive status and 
medication regimen complexity among older adults living in community, both cross-sectionally 
and over time?  
Hypotheses: The hypotheses of this study are as follows:  
H1A: There is an association between cognitive status and medication regimen complexity 
among older adults.  
H0A: There is no association between cognitive status and medication regimen complexity 
among older adults.  
H1B: There is an association between functional status and medication regimen complexity 
among older adults.  
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H0B: There is no association between functional status and medication regimen complexity 
among older adults.  
1.4 Study Objectives  
The objectives of this study are as follows: 
I. To characterize medication regimen complexity among community dwelling older adults 
in the United States 
II. To assess the association between medication regimen complexity and cognitive status  
1. Evaluate the association between medication regimen complexity and cognitive 
status at baseline  
2. Evaluate the association between medication regimen complexity and cognitive 
status after two years 
3. Compare factors that contribute to medication regimen complexity in participants 
with and without cognitive impairment. 
4. Assess the change in medication regimen complexity score and its association 
with change in cognitive status over two years  
III. Assess the association between medication regimen complexity and functional status  
1. Evaluate the association between medication regimen complexity and functional 
status at baseline  
2. Evaluate the association between medication regimen complexity and functional 
status after two years 
3. Compare factors that contribute to medication regimen complexity in participants 
with and without functional impairment. 
4. Assess the change in medication regimen complexity score and its association 
with change in functional status over two years. 
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1.5 Significance of the Study 
This study contributes to understanding the relationship between cognitive/functional 
impairment and medication regimen complexity in a nationally representative population of 
older adults. Older adults, who make up a significant percent of the US population, are more 
susceptible to the negative outcomes of medication use due to the higher chronic disease burden 
found in this population. This is the first study that will evaluate the association between 
cognitive/functional impairment and medication regimen complexity in nationally representative 
population of older adults living in the community in 2004 and 2006 and the change of 
medication regimen complexity over two years period. More importantly, the associated 
cognitive and functional decline in this age group also increases the risk of harm from complex 
medication regimens. This makes it particularly important to examine these populations. This 
study could assist healthcare providers in identifying older adult’s patients who may require 
cognitive and functional assessments and assessment of medication complexity prior to therapy 
initiation. These assessments ensure that medication regimes are tailored to individual patients. 
  In addition, this study will attempt to highlight the importance of cognitive and functional 
assessments in clinical settings in order to identify individuals who are at risk of poor adherence. 
This can help to prioritize older adult’s patients who need medication reviews and revision of 
their treatment plan to maintain adherence, which will help them to achieve maximal health 
benefits.  Furthermore, the results will help efforts to maximize medication adherence by 
increasing healthcare providers’ awareness of the need to minimize the complexity of medication 
regimens. 
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Chapter 2: Background and Literature Review 
 
The purpose of this study was to examine the association of cognitive and functional 
status with medication regimen complexity in older adults living in the community. This section 
will provide background information on the definition of medication regimen complexity, the 
definition and prevalence of cognitive impairment in older adults, the definition and prevalence 
of functional impairment in older adults, multiple medication use and medication regimen 
complexity in older adults, cognitive impairment and adherence in older adults, functional 
impairment and adherence in older adults, medication regimen complexity, adherence, and other 
clinical outcomes in older adults and a literature review of the evidence relevant to this research 
study, namely, literature regarding the association of cognitive or functional impairment and 
medication regimen complexity in older adults.  
2.1 Definition of Medication Regimen Complexity 
Medication regimen complexity has been a subject of study for decades,37 however the 
exact parameters of what constitutes complexity and how to measure these parameters has led to 
differing definitions of this construct throughout the literature. With increasing use of multiple 
medications, the impact of complexity is just beginning to be appreciated by researchers. The 
idea of polypharmacy, which is based on the number of medications an individual is taking, is 
not enough on its own to explain the large discrepancies seen with adverse drug events or 
adverse outcomes. It is also not sufficient for the evaluation of the impact of regimens on 
outcomes in intervention studies.38 Additionally; there is a sense amongst clinical providers that 
the concept of polypharmacy may not fully explain observed results for adverse drug events and 
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subsequent adverse outcomes. Medication regimen complexity, unlike polypharmacy, provides 
detailed and nuanced data for researchers and practitioners.38 Early studies defined medication 
regimen complexity as dose multiplied by the frequency of administration.37 Other studies 
considered medication complexity solely as the number of medications or the number of tablets 
taken per day. Other researchers went further to account for complexity by combining the 
number of doses per day, in addition to the number of medications taken, to make up the 
components of medication complexity.39–41 Another study evaluated the complexity of 
medications by multiplying the number of medicines administered by frequency of 
administration.42 
Previously, the term ‘regimen complexity’ has been used interchangeably with 
‘medication count’ in a manner similar to the concept of polypharmacy. This did not take into 
account other facets of complexity such as different dosage forms and dosing frequencies.3,43 
However, a patient’s compliance is influenced not just by the number of medications taken but 
also by other factors, which make up regimen complexity. These include the number of doses to 
be taken, the route of administration, the preparation steps prior to administration and variable 
administration schedules.37 To examine these factors, the Medication Complexity Index was 
developed by a graduate student (Kelly, 1988) to evaluate medication regimen complexity.44 
However, limitations in the original design made it quite difficult for users to record information. 
Due to these difficulties, George et al. (2004) redesigned the Medication Complexity Index and 
developed a 65-item medication regimen complexity index (MRCI) tool as a way to quantify 
several components of medication regimen complexity. This redesigned instrument, accounts for 
the dosage form (e.g. tablet, inhalation), dosing frequency (e.g. once a day, three time a day), and 
additional directions (such as crush the tablet, or take with food). Other information taken into 
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account in this tool includes multiple unit dosing (2 tablets, 2 puffs) and specific timing (e.g. at 
3pm).38 Weights were assigned to dosage forms, frequency of doses, and additional directions. 
Although number of medications is one contributing factor to the MRCI score, the 
definition of MRCI is different than the definition of polypharmacy38 because it also includes 
other aspects of the medication regimen.39 The MRCI is a widely used instrument in studies and 
has been validated in a study by George et al. on chronic obstructive pulmonary disease patients. 
To measure that prescription medication associated with that disease; the tool was validated by 
an expert panel who subjectively ranked six regimens to ascertain the criterion validity. This 
indicated strong agreement (Kendall’s W = .8, p = 0.001). The inter-rater and test-retest 
reliabilities for the total score and scores from the individual sections of the MRCI as ≥0.9 38. 
Further validation was done  by Libby et al. included not only prescription medications 
associated with the disease but also over the counter (OTC) medications and other prescription 
medications which are often referred to as patient-level MRCI (pMRCI).32’
45 The patient-level 
MRCI has been used to measure medication complexity in several patient populations including 
depressed geriatric patients, organ transplant patients, patients with heart failure, HIV patients, 
hypertensive patients, patients with diabetes, and patients on dialysis.46–51 Table 2.1 below shows 
examples of some MRCI components and their weighted scores. The full MRCI is included in 
Appendix A. 
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Table 2. 1 Medication regimen complexity index components and scoring 
Component category  Elements  Elements score  
Dosage form Once daily  
Three times daily  
Hour intervals (e.g. Q12 h) 
1 
3 
2.5 
Dosing frequency  Oral (e.g. tablet) 
Topical (e.g. creams, ointments) 
Eye drops   
1 
2 
3 
Additional direction  Break or crush table 
Take at specific time (e.g. in the morning)  
Relation to food (e.g. take with food) 
1 
1 
1 
Note: This table contains a subset of MRCI elements for demonstration purposes, the full MRCI can be 
found in Appendix A 
 
2.2 Definition and Prevalence of Cognitive Impairment  
The prevalence of cognitive impairment increases with age.52  Its effects impact families, 
carers, and health and social care providers as well as the patient.53 Cognitive impairment is 
defined as a state where a person has trouble learning new information, remembering things, and 
concentrating or making decisions which can affect them to function adequately and 
independently in everyday life.54 Cognitive impairment can range from mild to severe.54  
Mild cognitive impairment (MCI) is a transitional stage which falls between normal 
ageing and dementia, and is defined as “an overall mild decline across cognitive abilities that is 
greater than would be expected for an individual’s age or education, but is insufficient to 
interfere with social and occupational functioning, as is required for a dementia syndrome.”55 
Patients with mild, cognitive impairment often complain of memory loss but show no evidence 
of dementia. Individuals may start to notice some minor changes in their cognitive function, 
including a decline in cognitive abilities such as thinking skills and memory.52 These progressive 
changes are usually noticeable by the patients experiencing them or by other people around them 
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like a family member, however these changes do not significantly affect their functioning and the 
patients are still able to carry out their activities of everyday living.54  
In severe cognitive impairment, the patient loses the ability to understand the meaning of 
or to remember the importance of things and loses the ability to talk or write. The loss of such 
basic but important functions results in an inability to live independently.56,57 The underlying 
causes of mild cognitive impairment are not well understood however, there are some risk 
factors that are most strongly linked to mild cognitive impairment that are the same as those for 
dementia, which include a family history of the disease, progressing age, and chronic diseases 
such as cardiovascular disease in which blood vessels, including those that support brain 
function, experience reductions in blood flow.58 
The prevalence of mild cognitive impairment is between 3% and 19% in the older adult 
population, with an incidence of 8 to 58 cases per 1000 individuals per year.59 Cognitive 
impairment is associated with a higher risk for progression to dementia. The progression rates 
are estimated at 10% to 15% per year amongst older individuals with cognitive impairment 
compared to 1% to 2.5% among cognitively healthy older adults.27 A recent study done by 
Plassman et al. used data from the “Aging, Demographics and Memory Study (ADAMS study)” 
to estimate the incidence of CIND (Cognitive Impairment with no Dementia) and the progression 
of CIND to dementia during the follow-up period. The ADAMS study used a longitudinal 
design, and included individuals from all the regions of the US.62 The study reported that an 
estimated 5.4 million older adults (22.2% of the United States older adult population) had 
cognitive impairment without dementia. At follow-up, 11.7% of those with cognitive impairment 
had progressed to dementia.62 A range of diagnostic and screening tests are available to assess 
cognitive function. Some are more detailed than others, and different tests assess different 
cognition domains. The Health and Retirement Study used the Telephone Interview for 
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Cognitive Status (TICS). The TICS is a screening tool not intended for diagnostic purposes, and 
omits certain areas examined by other tests, such as visuospatial and executive function. 
Domains assessed by the TICS include orientation, attention, short-term memory, sentence 
repetition, immediate recall, word opposites, and praxis.63  
2.3 Definition and Prevalence of Functional Impairment  
Functional status is “an individual's ability to perform normal daily activities required to 
meet basic needs, and maintain health and well-being without support.”64,65 Functional ability is 
central to overall independence and is a key determinant of quality of life.66 Difficulties that 
substantially interfere with or limit role functioning in one or more major life activities is 
referred to as functional impairment.66  Individuals with functional impairment often need the 
assistance of another person to perform one or more daily activities.66 Functional impairment is 
assessed by many tools which could be self-reported or caregiver reported and characterized by 
being unable to carry out activities of daily living, which can be assessed using the activities of 
daily living tool (ADLs)  that assesses tasks such as getting out of bed, dressing oneself and 
performing personal hygiene. Instrumental activities of daily living (IADLs) tool assesses tasks 
such as eating, walking, shopping, housekeeping and preparing meals.66,64   
ADLs are the primary and fundamental elements of self-care. The inability to 
independently perform even one of these activities may signal the need for supportive services. 
IADLs are typically higher-level activities people must perform in order to remain independent 
in the community and are often a basis for assessment of needs for services to assist in 
maintaining independence.66,67  The decline of functional status in older adults can lead to an 
inability to live independently at home and predisposes them to social isolation. This decline can 
be accelerated by personal risk factors which vary from patient to patient and can lead to a rapid 
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decline in functional status, or can be slowed by the introduction of external support and the 
application of appropriate interventions.68,69  
Health promotion and halting functional decline in older adults is a longstanding public 
health policy issue in the United States.70 However, there is no general consensus regarding 
changes in the trajectory of late-life functional status and disability in the older adult population 
over time. Some argue that late-life functional status and disability for older Americans has 
never been better, while others argue that the situation has not been improving 71,72 With the 
general population getting older, there has been a proportional rise in the decline of functional 
ability.17 There has also been a concurrent rise in the prevalence chronic illnesses, which increase 
the risk of a decline in functional status.  
The presence of multiple illnesses often reduces the ability to compensate as one would 
with a diagnosis of a single illness. As a result of this, comorbidities in older adult patients may 
lead to greater disability than generally anticipated.17 Chronic disease includes conditions such as 
diabetes, cardiac disease, neurological conditions, cancer, obesity, and dementia. Some of these 
conditions are rare but very highly disabling like stroke, while other conditions such as arthritis 
are more common but may be less disabling.73  The disabling effect can vary depending on the 
task the patient is trying to perform. For example, heart disease is more likely to produce 
difficulty with tasks involving physical activity such as housework, while neurological 
conditions such as Parkinson’s disease may interfere with tasks requiring fine motor control.74 
Both the impairment and the underlying health condition should be addressed in older adults so 
that interventions can be developed to reduce the level of disability.  
The coexistence of two or more health conditions (comorbidity) can result in more 
disability. As the number of impairments increases from one to four, the percentage of persons 
reporting dependence on others for assistance with activities increases exponentially (7%, 14%, 
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28%, and 60% respectively).75 A recent study assessing functional status among individuals 65 
and older participating in Medicare managed care plans collected data longitudinally from 1993-
2007. The results of this study showed declines on all measures of function status (ADLs and 
IADLs). After an average of 8 years of follow-up, 36.6% of participants showed at least two new 
ADL limitations, 32.3% developed at least two new IADLs limitations.76 Among older adults 
admitted to medical hospital units, the prevalence of pre-admission ADL disability was 20.7% 
among those 60-69 years, and 41.2% for those aged 70 or older. The prevalence of pre-admission 
IADL disability was 29.6% among those 60-69 years and 62.9% among those aged 70 years and 
older.77 
2.4 Multiple Medications Use and Medication Regimen Complexity in Older Adults  
It has been well-documented that older adults in the United States are likely to be taking 
multiple medications concurrently.78,79 With medical advancements and public health 
improvements resulting in increased life expectancy, there are increasing numbers of older adults 
with multiple chronic conditions who require several medications to manage their conditions.80,81 
Older adults with multiple comorbidities are also more likely to experience cognitive and 
functional impairments.82 13% of older adults who have one or more chronic conditions also 
experience functional impairment and over 26% of older adults who have five or more chronic 
disease have functional impairment.82 Chronic conditions are also associated with cognitive 
impairment, with approximately 24% of all cases of cognitive impairment without dementia are 
attributable to chronic medical illness.62 Because cognitive and functional impairments are 
associated with chronic disease, it is not surprising that these individuals are more likely to use 
multiple medications, and more likely to be at risk for medication-related problems.81,83 
The use of multiple medications can easily result from following clinical practice 
guidelines for a small number of chronic conditions such as hypertension, osteoarthritis, chronic 
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obstructive pulmonary disease and diabetes.84,7 Multiple medications obtained from multiple 
prescribers and pharmacies, and the use of over-the-counter medications and alternative therapies 
such as herbal medicines contribute to medication-related problems.85 Along with the widespread 
use of multiple drugs, older adults are frequently prescribed medication therapy with varying 
doses, different frequencies and varying routes of administration,84 as well as various dosage 
forms such as tablets, inhalers or injections.86,87 A sample of older adults aged 65 years and older 
with a diagnosis of depression was randomly selected in ambulatory clinics at the University of 
Colorado and University of San Diego. The results of this study showed that the complexity 
score for individual were on average 17.62 (San Diego) and 19.36 (Colorado). Dosing frequency 
contributed to 57-58% of the MRCI score, with patients having an average of 7-8 unique dosing 
frequencies in their regimens. For additional directions attached to a patient medication (e.g. 
crush pill, take with food, taper dose),at  both sites, there was an average of 3 additional 
directions per regimen to clarify dosing.46 The increased use of medications is likely attributable 
to the concurrent increase in age-associated chronic conditions. A study by Libbyet al. (2013) 
showed that using patient-level MRCI scores which included prescription drugs and over the 
counter medications across four chronic diseases, found that MRCI was higher in the geriatric 
depression cohort when compared to other cohorts for other diseases. The next highest 
complexity was the diabetes cohort followed by the HIV cohort and the hypertension cohort. 
Across all cohorts, most older adults were using dosage forms other than tablet/capsule. Large 
numbers of participants also had at least three additional directions and at least three different 
dosing frequencies.32 As a result, the complexity of medication regimens increases making it 
more difficult for patients to comply with their planned treatments.38 Medication regimen 
complexity increases the difficulty of self-care in the home for older adults. 
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Although many factors in medication regimen complexity may contribute to how 
complicated a medication regimen is, each element of complexity may differ in the extent to 
which it contributes to total complexity and complicates the medication regimen. A study by 
Advinha et al. (2014) used the MRCI to assess medication regimen complexity in 
institutionalized older adults, and found that the factor with the greatest contribution to 
complexity was number of medications.88 Another study conducted by Wimmer et al. (2015) 
also showed that the number of medications was highly correlated with MRCI.36 In the Advinha 
study, when they compared regimens with the same number of medications, dosing frequency 
was most closely associated complexity (r=0.922), followed by dosage form (r=0.768) and then 
additional directions (r=0.742).88 A study by Elliott et al. (2011) also found that the most 
common regimen simplification implemented by hospitals was reduction in dosage frequency, 
which also led to reduction in the MRCI.89 Finally, a study by Libby et al. showed that among all 
contributing factors to patient-level MRCI scores, dosing frequency contributed the most 
complexity points to the MRCI score (55%–64%), followed by dosage form.32 Regardless of 
which component contributes the most to complexity, complexity itself is associated with 
detrimental outcomes for patients.89 Complex medication regimens can lead to clinical 
consequences from both medication over- and under-use, and as the complexity increases, the 
risk of administration error also increases.  Patients with complex medication regimens are less 
likely to fully comply with therapy compared to patients with simpler treatment regiomens.33 
2.5 Cognitive Impairment and Adherence in Older Adults 
Poor medication adherence is very common and is a major risk factor for health 
problems. This issue disproportionately affects older adults, as they are the highest users of 
prescription medications.90,91 Adherence can be defined as taking the correct amount of a 
medication at the right time while following the instructions given with the medication, such as 
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taking it with or without food.92 Older adults are at a higher risk of suffering the negative effects 
of non-adherence  with therapy, particularly due to the high prevalence of chronic comorbidities 
in this group.83 Management of chronic conditions often requires complex medication regimens, 
which is a known risk factor for poor adherence in older adults.29,93 
Self-management and the ability to perform self-care helps maintain patient 
independence and empowers the patient to achieve effective disease management. Age-related 
reductions in the function and mobility put older patients at a higher risk of non-adherence than 
younger patients. Declines in cognitive ability further compound the problem and can worsen 
adherence.21 Cognitive processes are required in order to manage a medication regimen on a 
daily basis. As a result, older adults with cognitive impairment are less likely to succeed in 
following complex medication regimens as intended by the prescriber.94 Cognitive impairment is 
among the most important risk factors for medication non-adherence in older adults. Non-
adherence is estimated to be almost three times higher in patients with cognitive impairment.95 
Cognitive impairment has also been shown to double the risk of non-adherence among older 
adults patients using antihypertensive medications.96  Patients with cognitive impairment often 
have trouble understanding and following treatment recommendations. Such individuals may 
forget doses or take a dose multiple times leading to inadvertent overuse. This is often related to 
impairment of higher-level cognitive functions such as executive function, which is essential for 
planning and monitoring medication use.92,94 Even individuals who retain the ability to perform 
basic tasks related to adherence, such as reading and being able to tell time, may be unable to 
comply with a complex regimen if elements of executive function such as planning and retaining 
information are impaired.97  
Adherence to a medication regimen requires understanding the dosing directions and 
schedule, which requires planning to be able to take the drug at a specific time or under specific 
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circumstances such as after a meal. The ability to recall instructions for responding to missed 
doses and follow through with related plans is also required.98  Deficits in executive function 
lead to impairments in the ability to create plans and to organize and carry out tasks. These are 
key skills involved in managing complex medication regimens, and as a result executive function 
deficits impair adherence to therapy.98 This can result in poor disease control, medication errors, 
increased risk of hospital admission, and loss of independence in the area of medicine 
management.99,100 Thus assessment of executive function and cognitive impairment will be 
critical to identifying older adults patients at risk for therapeutic failure due to poor adherence.92 
2.6 Functional Impairment and Adherence in Older Adults 
Age related and disease related changes are common among older adults and they often 
experience decreases in functional ability and greater difficulty in performing everyday tasks 101  
It is associated with a lower quality of life, a higher risk of health decline and contributes to 
health care costs.102  Functional decline can occur as a result of several factors including 
cognitive impairment, as it has long been part of the diagnostic criteria for cognitive impairment.  
A study by Farias et al. (2006) examined different types of cognitive impairment and their 
relationship with functional ability. This study found that compared to controls without cognitive 
impairment, individuals with mild cognitive impairment experienced more functional limitations, 
and individuals with dementia experienced an even higher level of functional impairment.103 
Individuals with such impairments often experience difficulty in adhering to medications due to 
these impairments.104  
Functional impairment can also result from other causes such as chronic disease that can 
result in reduced mobility and poor manual dexterity, leading to reduction in functional ability. 
When these abilities are necessary for taking medication, this can result in reduced adherence.105 
Medication adherence was examined among Medicare patients with heart failure. Individuals 
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experiencing functional impairments were found to have lower levels of adherence over a one-
year period.106 Another study compared antihypertensive medication adherence in patients with 
and without functional impairment using medical claims data of the National Health Insurance 
(NHI). This study also found that adherence was lower in individuals with functional 
disabilities.107   A recent study examined the impact of impaired mobility on medication 
adherence in older adults. According to this study, patients with severe or moderate mobility 
impairment had lower adherence rates to medication (62% and 66% respectively) than 
individuals with no mobility impairment (73%).108 Reduction in functional ability often makes it 
difficult for patients to manage their medications and leads to considerable difficulties with tasks 
such as opening child-proof containers. Several medication types such as nebulizers, inhalers and 
eye drops require physical manipulation in order to administer them correctly. Conditions which 
impair joint function or manual dexterity may make the use of these medications difficult.109 Due 
to these limitations, individuals with functional impairment are often at greater risk of 
medication non-adherence.110,111 
2.7 Medication Complexity, Adherence, and Other Clinical Outcomes in Older Adults 
Previous research has shown a correlation between negative clinical outcomes in older 
adults and complex medication regimens. Medication regimen complexity is reported to be 
associated with self-administration errors.40 Family caregiver medication administration 
problems were also found to increase with medication regimen complexity, leading to the 
suggestion that complex medication regimens of individual patients could be used to identify 
caregivers at risk of experiencing difficulties administering medication.112 Medication regimen 
complexity is also associated with higher rates of hospitalization, 113’
114 and increases in MRCI 
score increased the probability of adverse drug events (ADE).113 Higher MRCI scores were 
associated with an increase in all-cause mortality.115 Complex medication regimens may be 
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particularly detrimental to patients who have experienced hospitalization. More complex 
medication regimens have been shown to be inversely associated with the probability of 
discharge directly to home from hospital.116 In addition, complex medication regimens also have 
an impact on patient knowledge of new medications added to their regimens. Newly prescribed 
medications are common, with an estimated 40% of patients discharged from the emergency 
department receiving at least one new medication. In patients with already complex regimens, 
the addition of another medication to an already complicated list can make it more difficult to be 
knowledgeable about their medications.117    
Poor adherence to therapy has been shown to have a negative effect on patients and to 
result in higher medical costs.23 The relationship between medication regimen complexity and 
adherence has been examined in previous studies, demonstrating that high MRCI negatively 
impacts adherence in older adults.118’
119 The aim of treatment with medication is to optimize the 
benefit from medication while minimizing side effects. Unfortunately, this balancing act often 
requires detailed directions, which make treatment plans more complicated. Older adults 
generally have more difficulty adhering to complex treatment plans.93 Both overall complexity 
and specific components of complexity can interfere with adherence.25 Number of medications is 
negatively associated with adherence that is, the presence of more medications was associated 
with worse adherence.120 Also having simple or complex dosing schedules would affect 
adherence as adherence to therapy is lower with more complex dosing schedules, and this has a 
negative impact for patients.121 A retrospective cohort study investigated adherence in patients 
with type 2 diabetes taking oral anti-diabetic medications, and reported that complex treatment 
plans with more frequent dosing schedules were linked with poor adherence to therapy.122 
Patients on twice-a-day treatment plans had lower adherence over time than those on once daily 
dosing regimens.123 Having the patient on lower dosing frequency is better and recommended for 
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improved adherence.124  Other elements of complexity such as drug instruction and the dosage 
form can also impact adherence. Less complicated regimens with fewer doses and little or no 
special instructions (such as food and storage requirements) were associated with better 
adherence. 125 Multiple dosage forms reduced the adherence rate to treatment regimens with 
multiple components such as systemic corticosteroids and inhaled and long-acting 
bronchodilators in patients with severe asthma.126 These factors all play a part in influencing 
patient adherence to treatment, and are therefore are important considerations in promoting good 
adherence to medication therapy. 
2.8 Association of Cognitive/Functional Impairment and Medication Complexity in Older 
Adults 
Introduction  
The population of the United States is aging rapidly. By 2050, the population aged 65 and 
over is projected to be 83.7 million, almost double the number of older adults that there were in 
2012.10 Older adults also are the largest consumers of medication in the US, largely due to an 
age-associated increase in chronic conditions.1 The management of these chronic conditions 
often requires the use of multiple medications for a prolonged period of time.79 Because of this, 
multiple medication use is a common aspect of providing health care to older adults, leading to 
increase in prescribed medication use by older adults2. In addition, older adults are often 
prescribed medications with multiple dosing schedules, multiple dosage forms such as tablets 
and inhalers, and multiple routes of administration, all of which lead to complex treatment 
plans.127 Higher medication regimen complexity increases the risk of poor adherence.118’119 Older 
adults are also at risk for decline in their cognitive and functional abilities,13 which can act as 
barriers to compliance with a prescription medication regimen.20 It is therefore important to 
understand the association of cognitive and functional impairment with medication regimen 
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complexity in older adults.  The objectives of this literature review are to identify and synthesize 
information from studies of cognitive or functional impairment and medication regimen 
complexity in older adults, to determine the factors associated with medication regimen 
complexity in older adults, and to identify gaps in the literature that should be examined. 
Methods 
The literature search was conducted from January 1998 to January 2018 in 
PUBMED/CINAHL and Google Scholar. In PUBMED and CINAHL, the search used the terms 
“poly-pharmacy” OR” medication” OR “medicine” OR “pills burden” AND “treatment 
complexity” OR “regimen complexity” OR “medication regimen complexity” AND “cognitive 
status” OR “cognitive impairment” OR “cognitive decline” AND “functional status” OR 
“functional impairment “OR “functional decline”.  In Google Scholar, targeted searches using 
individual terms or combinations of terms were used to find additional articles. Title and 
abstracts were first screened for inclusion and exclusion criteria, and duplicates were removed. 
Full-text articles were then screened for eligibility. Inclusion criteria included: (1) a study 
population consisting of older adults aged 60 years or older; (2) Observational studies or 
intervention-based studies; (3) cross sectional or longitudinal studies; (4) was conducted in or out 
the United States; and (5) the assessment of cognitive or functional impairment in the study 
population. Exclusion criteria included: (1) not using a validated tool to assess complexity of 
medication regimen; and (2) journal articles not written in English. The search over all databases 
yielded 225 results. In addition, the citations included in review articles were searched for 
relevant literature that was not captured in the literature search. After applying the inclusion and 
exclusion criteria at the title, abstract, and full-text screening stages, a total of three original 
research articles were found. The flow of articles throughout these stages is contained in Figure 
2.1 Articles are summarized in Table 2.2 
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Articles based on older adults and looking at the association 
between cognitive/functional impairment and mediation 
regimen complexity or the factors associated with medication 
regimen complexity in older adults (n=3) 
 
Studies identified through 
sources searching 
(n=225) 
Records after duplicates removed 
(n=68) 
Full-text articles assessed 
For eligibility 
(n=28) 
Abstracts were included 
for further analysis 
(n=157) 
 
Articles did not meet the inclusion 
criteria, such as intervention or 
observational studies not examining 
the associations of interest (n=129) 
Articles that were not dealing with the 
association between cognitive or 
functional impairment and medication 
complexity (n=25) 
Figure 2.1 The Flow of Articles Throughout the Stages of Literature Review 
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Table 2. 2 Summary of Literature Assessing the Relationship Between Cognitive/Functional 
Impairment and Medication Complexity Among Older Adults 
 
 
 
 
 
  
Study Country Setting and sample 
size 
Assessment Finding 
 
 
(Herson et al. 2015)34 
 
 
 
Australia 
 
People aged 65 years 
and older living in 
LTCFs (n= 383) 
 
 
 
To investigate factors 
associated with 
medication regimen 
complexity in older 
resident living in LTCFs 
 
 
Independence in activities 
of daily living (ADLs) and 
dementia were associated 
with lower regimen 
complexity. 
 
 
 
(Wimmer et al. 2015)36 
 
 
 
 
Sweden 
 
 
People aged 60 years 
and older in 
community 
and in residential 
aged care, living in 
Central Stockholm 
(n=3348) 
 
 
 
To investigate factors 
associated with 
medication regimen 
complexity in older 
people 
 
 
Medication regimen 
complexity was lower in 
participants with cognitive 
impairment. No significant 
association was found 
between (ADLs) and 
regimen complexity. 
 
 
 
 
(Lee et al. 2012)35 
 
 
 
 
USA 
 
 
US. Older population 
aged 70- to 79-years, 
(n=3075) 
 
 
 
To evaluate whether 
cognitive impairment is 
associated with 
medication complexity 
for prescription and 
over-the-counter (OTC) 
medications 
 
 
Medication regimen 
complexity for prescription 
and OTC medications was 
lower in participants with 
cognitive impairment 
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Results: Summary of Studies 
Two studies assessed the association between cognitive impairment and medication 
regimen complexity in two different settings. One study assessed dementia and its association to 
medication regimen complexity. The study by Lee et al. (2012) found that cognitive impairment 
was associated with lower prescription complexity after adjusting for other health status, 
demographics, and access to health care (RR 0.89; 95% CI 0.80 to 0.99). The number of 
prescription medications was not significantly different between cognitively impaired and 
cognitively intact individuals. Therefore, the lowering in the prescription medication complexity 
was not due to lowering in the prescription usage but rather due to less complex dosage from, 
and less dosage. Interactions between cognitive impairment and each chronic condition were 
assessed and did not produce statistically significant results. Cognitive impairment was also 
associated with lower over the counter (OTC) medication complexity (RR 0.76; 95% CI 0.64 to 
0.93). The number of the (OTC) medications was also lower for those with cognitive impairment 
(RR 0.76; 95% CI 0.66 to 0.88). Thus, the decreased OTC complexity likely reflects a decreased 
number of OTC medications, rather than a difference in other components of complexity.35 
The study by Wimmer et al. (2015) found that among older adults, predictors of being in 
the highest MRCI quintile were older age (OR=1.04, 95%CI 1.02;1.05), not living at home 
(OR=0.35, 95 % CI 0.15;0.86), greater chronic disease (OR=2.17, 95 % CI 1.89;2.49), good 
cognitive performance (OR=1.06, 95%CI 1.01;1.11), self-reported pain during the last 4 weeks 
(OR=2.85, 95%CI 2.16;3.76), and receiving help in sorting medications (OR=4.43 95 % CI 
2.39;8.56) in comparing to those in lowest quintile. This study did not find a significant 
association between ADL score and medication regimen complexity score (OR=1.15, 95%CI 
0.88; 1.52).36 The study by Herson et al. (2015) assessed the association between several chronic 
diseases and medication regimen complexity. This study found that diseases associated with 
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higher complexity included diabetes, heart failure and pulmonary disease. This study also 
evaluated functional ability using activities of daily living (ADLs) and dementia, found that ADL 
and dementia were inversely associated with high regimen complexity (OR: 0.72, 95% CI: 0.62–
0.84), (OR: 0.34, 95% CI: 0.17–0.67) resprectivey.34 
Discussion 
This review was conducted to understand and summarize the current literature on the 
association between cognitive/functional impairment and medication regimen complexity among 
older adults. The search yielded three studies, out of which two were focused on the factors 
associated with medication regimen complexity in older adults and one study assessed the 
association between cognitive impairment and medication regimen complexity in older adults. 
Lee at al. (2012) evaluated whether cognitive impairment was related to medication 
regimen complexity for both prescription and over-the-counter (OTC) drugs. They found that 
cognitive impairment was associated with lower prescription complexity and lower OTC 
complexity. The authors suggested that prescribers may have simplified medication regimens to 
make the medication management easier for people with cognitive impairment. They also tested 
the difference in number of prescriptions and OTC medications between those with and without 
cognitive impairment and found that only OTC medication was significantly lower in those with 
cognitive impairment, and number of prescription medications was non-significantly lower. They 
attributed most of the reduction in prescription medication complexity to lower complexity from 
form and dosage frequency.  Although it provided useful insights, Lee et al. (2012) did have 
several limitations. This study used a population of older adults in two US cities, Memphis, TN 
and Pittsburgh, PA. It is possible that prescribing patterns, population demographics, and 
population health may differ between these cities and other parts of the United States, limiting 
generalizability of the results. Eligibility for this study was also restricted to individuals who 
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were free of functional limitations, including having the ability to walk without an assistive 
device. These restrictions may have limited the representativeness of the study population and 
may make it difficult to generalize the results to other older adults. 
The other two studies, Wimmer et al. (2015) and Herson et al. (2015), were conducted to 
investigate factors associated with regimen complexity in older adults.  Both of these studies 
occurred outside of the United States. Wimmer et al. used data from the Swedish National Study 
of Aging and Care in Kungsholmen (SNAC-K), and Herson et al. used data from six long-term 
care facilities in Southern Australia. These countries differ from the United States which may 
limit the generalizability of their results to the United States. The results in Wimmer et al. 
showed that participants with the most complex regimens had higher cognitive scores than 
participants with less complex regimens. The authors noted that this was consistent with the 
findings of Lee et al. and supported the idea that prescribers might have simplified medication 
regimens to facilitate easier medication management in people with cognitive impairment. 
However, Wimmer et al. mentioned that their results should be interpreted cautiously because 
there was only a small variation in Mini Mental State Examination score across complexity 
groups. Finally, Herson et al. (2015) focused on a population receiving assistance from nurses 
and independent living facilities, which means that their results are unlikely to be applicable to 
community-dwelling older adults who must manage their own medications.  
Both Wimmer et al. and Herson et al. assessed the association between medication 
regimen complexity and functional impairment (as measured using the index developed by Katz 
et al.128). Wimmer et al. showed no association between functional impairment and medication 
regimen and did not interpret this result further in their discussion. Herson et al. reported that 
independence in ADLs was associated with lower medication regimen complexity, but also did 
not interpret this result in their discussion, which suggests that they may interpret ADL 
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impairment as being a manifestation of dementia. Herson et al. also stated that clinicians 
discontinued or ‘deprescribed’ medications to residents with reduced life expectancy.  The 
inconsistent results for the relationship between functional impairment and medication regimen 
complexity make it difficult to draw a clear conclusion from the existing literature. Additionally, 
it would be desirable to investigate functional impairment using both ADLs and IADLs to obtain 
more clear and precise data about functional ability. All of the studies included in this review are 
cross sectional in design, which does not allow for the examination of changes over time. A 
longitudinal study would be desirable to examine how cognitive and functional status is 
associated with changes in medication regimen complexity over time. Additionally, no study has 
investigated association between prescription medication regimen complexity and cognitive or 
functional impairment in a nationally-representative dataset. This study will be the first study to 
examine the relationship between cognitive/functional impairment and prescription regimen 
complexity in older adults using a longitudinal design and nationally-representative data. 
Conclusion 
The review of the literature suggests that older adults with good cognition may have 
higher medication regimen complexity than those with cognitive impairment. Two studies 
provide two different results for the association between functional impairment in ADL and 
medication regimen complexity, with one study reporting no significant association, and the 
other reporting that independence in ADLs was inversely associated with high regimen 
complexity. However, most of these studies used data from outside of the United States and had 
other restrictions that may limit their generalizability. There is a need for further studies 
investigating the association between cognitive/functional impairment and medication regimen 
complexity, particularly studies using a longitudinal design and a nationally-representative 
sample.  
29 
 
 
 
Chapter 3: Methods 
 
3.1 Data Source 
This study used a nationally representative sample of individuals aged 65 and over, using 
data from the Health and Retirement Study (HRS). HRS is nationally representative longitudinal 
survey of more than 37,000 individuals over age 50 living in more than 23,000 households in the 
United States. The HRS is supported by the National Institute on Aging and the Social Security 
Administration.  The survey began in 1992 and is conducted every two years, following the same 
cohort of adults age 50 years or older, with new individuals added to the cohort at each wave. 
The HRS collects data on physical and mental health, family support systems, financial status, 
insurance coverage, and retirement planning. The HRS data is collected by interviewing the 
participants either in person or via a telephone interview. For individuals who are unable to 
complete the interview personally, a proxy completes the interview on their behalf. The main 
HRS survey is a free and publicly available data set, while some specialized sub-components of 
the survey are considered sensitive information and require a special approval to access 
restricted-use data. This study used data from the HRS surveys administered in 2004 and 2006, 
and also used data from the Prescription Drug Survey (PDS) sub-component of the HRS 
administered only in 2005 and 2007. An additional follow-up was administered in 2009 (the 
HRS 2009 Health and Well-Being Study), however the data release for the 2009 study did not 
include the detailed descriptions of participants’ prescriptions, and therefore was not used for this 
study.   
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3.2 Study Design 
This study used a retrospective cohort design, longitudinally following individuals over a 
two-year period. Baseline data came from the 2004 HRS questionnaire and the 2005 PDS 
questionnaire. Follow-up data came from the 2006 HRS questionnaire and the 2007 PDS 
questionnaire. The data from these years was used to assess the association between medication 
regimen complexity and cognitive/functional status at baseline and to assess the change in 
medication regimen complexity over a two-year period. 
3.3 Eligibility of Study Participants 
This study included respondents who, at baseline in 2004, were age 65 years or older and 
living in the community. In order to be eligible, participants must have been present in waves 7 
(2004) and 8 (2006) of the HRS and must have completed the 2005 and 2007 PDS 
questionnaires. Participants with missing data for the outcome variable (medication regimen 
complexity) or the main predictors (functional or cognitive status) were excluded. In addition, 
participants who lived in a nursing home at baseline or who were interviewed by proxy at 
baseline were excluded. Thus, the study sample is representative of community-dwelling older 
adults aged 65 years or older. 
3.4 Outcome Variable 
 The outcome under study was medication regimen complexity, which was assessed 
using a modified version of the medication regimen complexity index (mMRCI). the modified 
version of the tool was done and was administered by Lee et al.35 The original MRCI is a 
validated tool developed by George et al. (2004). The MRCI has strong inter-rater and test-retest 
reliability.38 The MRCI is a 65-item tool designed to quantify three components of medication 
regimen complexity. MRCI component "A" scores dosage form (e.g. tablets, injections, nasal 
spray) as a contributor to complexity, component "B" scores dosage frequencies (e.g. once a day, 
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every 12 hours) as a contributor to complexity and component "C" scores additional instructions 
(e.g. “break the tablet in half” or “take with food”) as a measure of complexity. Each dosage 
form is counted only once within a regimen. For example, if a patient's regimen consists of four 
tablets that are taken orally, their MRCI component “A” sub-score would be one. The MRCI 
component "B" measures dosing frequency (e.g. once a day, every 12 hours, alternate days) for 
each medication. A weight is given to each medication frequency, with higher weights assigned 
to greater frequencies. For example, if a patient is taking six medications with a frequency of 
once a day for each medication, the MRCI component B sub score would be six. MRCI 
component “C” measures additional directions (e.g. crush pill, take with food, taper dose). A 
weight is given for each instruction per medication. For example, if a patient is on a single 
medication that needs to be crushed and taken with meals, the component C score for that 
medication is two. The Medication Regimen Complexity Index is a summary score of all three 
components.  
There is no limitation to the number of medications or special directions that may be 
counted for a patient, and as a result the MRCI is an open index without an upper limit to the 
possible range of scores.38 For the purpose of this study, a modified version of the medication 
regimen complexity was created to account for the lack of information about additional 
instructions in the HRS 2007 Prescription Drug Study. For consistency, the same modified scale 
was applied to the 2005 data. The modified MRCI (mMRCI) score was calculated using the 
dosage forms and dosage frequencies with the same weightings applied as in the MRCI except in 
the scoring for frequencies in 2005, were coded as time per day not time per hrs. (for example: in 
2005 some phrases like “take one tablet every 12 hrs.” the frequency was giving a score of 2 
instead of 2.5 to ensure consistency across years. Details regarding dosage forms/dosage 
frequencies and their assigned weights are shown in the original MRCI tool that is attached in the 
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appendix A.  The modifications to the MRCI resulted in a lower complexity score than the full 
MRCI score since points for additional instructions were not included. As with the MRCI, higher 
mMRCI scores indicate greater medication regimen complexity. In the analysis, the mMRCI was 
used as a continuous variable. 
3.5 HRS Prescription Drug Study   
HRS 2005 Prescription Drug Study 
The HRS 2005 Prescription Drug Study is a supplemental study that was conducted in 
2005. It is the first wave of a two-wave mail survey designed to track changes in prescription 
drug utilization. The PDS was intended to capture changes in prescription drug use associated 
with the implementation of Medicare Part D in 2006, with the 2005 wave recording data prior to 
the implementation of this program. The sample for the Prescription Drug Study (PDS) was 
drawn from respondents to the main HRS survey in 2004. This questionnaire also included a 
section containing detailed medication data, including drug names and information on dosage. 
HRS 2007 Prescription Drug Survey 
The HRS 2007 Prescription Drug Study (PDS) is the second wave of the PDS, conducted 
in 2007 after the rollout of Medicare part D. The second wave was designed to capture similar 
information to the first wave, but post-implementation. The sample for the 2007 wave of the 
PDS consisted of everyone from the original 2005 sample who responded to either the PDS 2005 
or to the HRS interview in 2006. 
3.6 Drug information in HRS 2005 and 2007 Prescription Drug Study 
The survey used in the 2005 Prescription Drug Study asked the participants to provide 
information about each of the different medications they were taking and asked them to list all of 
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their prescribed medications. Space was provided in Section E to list up to ten prescription 
medications. Participants taking more than ten medications were asked to provide detailed 
information about the ten medications they considered to be the most important, and then to list 
all remaining medications in Section F. In section E, participants were asked to provide 
information from the label on the prescription bottle such as the name and dose of the medication 
(e.g. “Phenytoin (Dilantin) 100 mg”) and dosage instructions such as “Take one capsule by 
mouth as directed in the morning and at bedtime.” Section F asked for drug names only and did 
not include any other details. 
  The same instructions were used to collect prescription medication data in the 2007 
Prescription Drug Study. However, in the 2007 survey, medication details in section E were 
provided in a different format. The 2007 version of section E contained separate fields for 
medication name (generic and brand name), medication strength (mgs or other units), format/unit 
(e.g. capsule, tablet, inhalant, liquid, drop, other), and dosage frequency instructions (number of 
units and number of times per day/week/month). Because the data fields provided about 
medication regimen complexity components differed between the two years, data recoding was  
necessary. The steps involved in the recoding process are shown in Table 3.1 below. 
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Table 3. 1 Summery of the Steps Involved in the Recoding Process of the mMRCI 
Steps 
1. (In 2005) All medication instructions, such as “Take one capsule by mouth in the morning and at 
bedtime” and were extracted and exported to an Excel spreadsheet to be manually interpreted and coded 
in a manner consistent with the 2007 drug variables. 
Details: 
 Scoring was based on the original MRCI as described in Appendix A, except where specified 
below 
 Dosage frequencies given in hours, such as “every 12 hours” or “every 6 hours” were converted 
to number of times per day and scored accordingly. (This differs from the original MRCI, in 
which “every 12 hours” was scored as 2.5, but “twice per day” was scored as 2.) 
 If prescription instructions were provided in a foreign language, they were translated using 
Google Translate and then coded 
 In instructions where multiple dosage frequencies were provided (such as “3-4 times per day”) 
the more conservative (lower) score was assigned  
 Drugs for which a dosage frequency could not be reliably determined but where a dosage form 
was included were retained in the MRCI calculation.  
 
2. (In 2007) All medication instructions such as (inhalant, drop, other) were extracted and exported to 
an Excel spreadsheet to be manually interpreted and coded. Lexicomp® and drugs.com were used to 
check the applicable sub format based on format, brand name, generic name and the strength of the drug 
e.g. “1 drop daily” the brand name, generic name and the strength of the drug would be used to 
check the Lexicomp® and drugs.com databases to determine whether the medication was 
eardrops or eyedrops. 
 
3. (Both years 2005 and 2007)  
 For drugs with ambiguous dosage forms where the Lexicomp® or drugs.com databases found 
multiple plausible matches, and the forms of the plausible matches would have different MRCI 
scores, the form with the lowest MRCI score was used.  
e.g. for a drug such as insulin, which can be available as a vial (score=4) or a prefilled 
syringe (score=3) with identical strength and brand name, the lower score (3) was used 
to calculate the MRCI 
 Drugs for which a dosage form could not be reliably determined but where a frequency was 
included were retained in the MRCI calculation.   
 Drugs for which no information on dosage form and no information on frequency were 
available, were excluded from the MRCI calculation. 
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3.7 Creating the Complexity Variable and the Total Number of Medications 
Scoring Procedure for the mMRCI 
The mMRCI was computed by adding the summary scores for dosage form and 
frequency from all of an individual’s prescriptions. Prescriptions with partial information (e.g. 
missing form but known frequency, or missing frequency but known form) had all available 
information counted towards the score. Prescriptions for which both form and frequency were 
missing were considered invalid and did not contribute to an individual’s mMRCI score. 
Individuals for whom all listed prescriptions were invalid were excluded. Some individuals in 
2007 were found to have reported implausible values for drug frequency, such as reporting that a 
prescription was taken 90 times per day. These individuals after applying the inclusion and 
exclusion were 26 participants and were excluded from the study. 
Creating the Total Number of Medications 
The variable for number of medications was created based on the number of prescriptions 
participants reported in section E. Because section E allowed for a maximum of 10 prescriptions, 
this created a maximum value of 10 for this variable. Although participants were able to report 
additional drugs in section F, section F did not provide details about drug frequency and format, 
so these drugs could not be counted towards a participants mMRCI score. The PDS 
questionnaire also included a question about how many drugs a participant took regularly, where 
participants were able to provide a numeric answer with no upper limit, however, because dosage 
form and frequency information for any drugs not reported in section E would not be available, 
this variable was not suited for use in the present study.  Total number of drugs was created by 
taking the number of prescription medications reported by each individual in section E and 
subtracting the number of medications for which both the frequency and the format were 
missing, so that drugs that provided no information towards the mMRCI score would be 
excluded.  
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Individuals who had no prescriptions reported in section E, but who had answered “yes” 
to earlier questions about medication use in section A were given a missing sample weight by the 
PDS. All individuals with a missing PDS weight were excluded. Individuals who did not 
complete section E but who had earlier reported that they were not using medications had 
positive sample weights and were not excluded and were assigned a complexity of 0. After 
scoring, the 2005 and 2007 data prescription drug surveys were merged. The two merged years 
of the PDS were then merged with the HRS RAND data. 
3.8 Predictor Variables 
The main predictors under study were cognitive status and functional status. 
Cognitive Status 
Cognitive status as measured using the total cognition score from the HRS data. This 
score was calculated as a sum of several tests comprising the Telephone Interview for Cognitive 
Status (TICS) battery.129 The highest possible score was 35 points, with lower scores indicating 
poorer cognitive function. Tests in the battery included total recall, a test of working memory, 
and the mental status test. Total recall consisted of immediate free-recall (ability to remember a 
list of 10 nouns the respondent has just heard) and delayed word recall (ability to remember the 
same words after 5 minutes). The test of working memory was the serial 7s test, which asked the 
participant to subtract 7 from 100, and to continue subtracting 7 from each subsequent number 
for a total of five trials. The test of mental status included backward counting from 20 to 10, date 
naming where respondents were asked to report “today’s date”, object naming where respondent 
asked “What do you usually use to cut paper?” and “What do you call the kind of prickly plant 
that grows in the desert?” and president/vice president naming where respondents were asked to 
name the current president and vice president of the United States.  
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Cognitive score was used as a continuous variable when modeling relationships with 
overall complexity (at baseline, at follow-up, and longitudinally). For models examining sub-
components of complexity, cognitive impairment was dichotomized using cutoffs identified in 
previous research using the HRS, with scores of 11 to 35 classified as “normal cognitive 
function” and scores of 10 or lower classified as “cognitive impairment”. 130’131 
Functional Status  
Functional status was measured using Activities of Daily Living (ADLs)128, which are the basic 
activities performed at home, and Instrumental Activities of Daily Living (IADLs)132, which are 
the activities required for living independently in the community. The ADLs scale included 
questions assessing the difficulty respondents experienced in walking across a room, dressing, 
bathing, eating, and transferring (getting in and out of bed). The IADL scale included questions 
assessing the difficulty respondents experienced when using the telephone, shopping, preparing 
food, taking medication, and handling finances. Each score (ADL and IADL) ranged from 0-5, 
with a higher score indicating that a respondent was able to perform a larger number of activities 
without impairment. The scores were summary variables constructed as counts of the number of 
ADL or IADL activities with which individuals reported at least “some difficulty”, so an 
individual with a score of 0 reported impairments in 0 activities, while an individual with a score 
of 5 reported impairments in all 5 activities. 
Both scores were used as continuous variables when modeling relationships with overall 
complexity (at baseline, at follow-up, and longitudinally). For models examining sub-
components of complexity, each score was dichotomized into categories of “no impairment” and 
“one or more impairments”. 
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3.9 Covariates  
Socio-demographic covariates included age, gender, marital status, income (annual 
household income in dollars), years of education (0 to 17+), race, perceived health status, history 
of hospital stay in the previous two years, health insurance coverage, Medicare part D status, 
depression, number of people in the household, and number of chronic conditions. 
Demographic Data Variables 
Older adults were categorized into three age groups (in years): 65-74, 75-84, and 85 and 
above. Gender was categorized as male or female. Race was categorized as white, black, or 
other. Marital status was categorized as married or non-married (non-married includes never 
married, divorced, separated, and widowed). Annual income was grouped into five categories 
based on rounded cutoffs for the 25th, 50th, 75th, and 95th percentiles. This resulted in categories 
of $0-$15,999, $16,000-$28,999, $29,000-$50,999, $51,000-$134,999 and over $135,000. Years 
of education was classified as “no degree”, “high school”, “some college”, and “college degree”. 
Number of individuals in the household included the respondent, and was grouped into 
categories of 1, 2-3, 4 or more. 
Access to Health Care Variables 
Insurance coverage status was treated as a dichotomous variable based on whether the 
participant had any form of coverage (covered by federal government health insurance program, 
covered by health insurance from a current or previous employer, covered by other health 
insurance) or no coverage. Medicare Part D prescription coverage was introduced between the 
2005 and 2007 waves, and thus was included only in follow-up and longitudinal models, but not 
in the baseline models. In models that included Medicare Part D, it was treated as a type of 
insurance coverage and incorporated into the dichotomous insurance coverage variable. History 
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of hospital stays in the previous 2 years was treated as a dichotomous variable coded as yes or 
no. 
Health Status Variables 
The health status variable was obtained from the survey question asking participants to 
self-rate their current general health condition. Excellent, very good and good were grouped 
together and the variable was categorized as (excellent/very good/good, fair, or poor). Number of 
chronic conditions was based on the number of questions to which participants had answered yes 
when asked “Has a doctor ever told you that you have [condition]?” Conditions included in the 
questionnaire were 1) high blood pressure or hypertension 2) diabetes or high blood sugar 3) 
cancer or a malignant tumor of any kind except skin cancer 4) chronic lung disease such as 
chronic bronchitis or emphysema 5) heart attack, coronary heart disease, angina, congestive heart 
failure, or other heart problems 6) stroke or transient ischemic attack 7) emotional, nervous, or 
psychiatric problems and 8) arthritis or rheumatism. The number of chronic conditions variable 
was then categorized into none, 1-2, 3-4, and 5 or more. Depression was measured using a 
continuous score derived from the Center for Epidemiologic Studies Depression (CES-D) scale 
and was dichotomized into depression or no depression.  
3.10 Missing Data 
Following the initial application of inclusion and exclusion criteria, individuals were 
checked for missing or invalid data. 11% of individuals who had met the initial criteria were 
excluded for missing or invalid data on one or more variables. 2% of individuals had only invalid 
prescriptions (prescription for which no frequency or format data was available). A further 8% of 
individuals had not completed the prescription inventory despite answering “yes” to one or more 
questions about taking medication. 1% of participants were excluded for reporting implausibly 
high dosage frequency in 2007. For all other variables, including the main exposures (cognitive 
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and functional impairment) less than 5% of participants had missing data.  Complete case 
deletion was used to address the problem of missing data. To ensure that this deletion did not 
create selection bias, individuals who were excluded for reasons related to the prescription 
inventory (missing prescription inventory, invalid entries, or implausible dosage frequencies) 
were compared to the rest of the sample on all major covariates using chi-square tests or Fisher 
exact tests (depending on cell size). Individuals who were missing data on complexity were 
significantly more likely to be unmarried, have a low income, more likely to have less than a 
high school education, and more likely to be African American.  
3.11 Statistical Analyses  
Descriptive statistics were used to describe the baseline characteristics of our sample. 
Continuous variables were expressed as the weighted mean ± standard deviation (SD). 
Categorical variables were expressed as the unweighted frequency and weighted percent. For 
both continuous and categorical variables, results were weighted to account for complex sample 
design.  To ensure comparability to the general HRS population, including in more recent years, 
descriptive statistics were repeated using all participants in the 2012 wave of the HRS. The 
results of this 2012 descriptive analysis can be found in Appendix B. 
The predictors were then examined for compatibility with the assumptions of the linear 
regression model. For continuous predictors, linearity of association with the outcome, normality 
of residuals, and homoscedasticity of residuals were checked. The residuals were not normally 
distributed, so the outcome variable complexity was log transformed, after which the regression 
assumptions were met. Residuals were also examined to detect extreme outliers. For categorical 
predictors, equal variance of residuals across categories was checked. All analyses were 
conducted using survey procedures to account for complex sample design. Because it is possible 
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that the structure or composition of the PDS sample may have differed from that of the broader 
HRS sample, weights specific to the PDS sample were used instead of the original HRS weights. 
For aim I, characterization of medication regimen complexity among community 
dwelling older adults, distributions of each complexity sub-component were checked for 
normality. Because non-normal distributions were detected, the median and inter-quartiles ranges 
were used to summarize the total mMRCI score and each portion of the mMRCI calculation 
(number of medications, dosage form and dosage frequency). Dosage form and frequency were 
treated as categorical variables and were summarized by reporting the most prevalent dosage 
form and the most frequently observed dosage frequency among the population.  
For the analysis for aims II and III, sub-aims 1, 2 (assessing the association between 
medication regimen complexity and cognitive and functional status), survey-weighted 
multivariable linear regression was used to examine the cross-sectional association between 
mMRCI and each exposure (cognitive status and ADL status, and IADL status).  For the 
association between mMRCI score and cognitive status, multivariable linear regression models 
were performed cross-sectionally at baseline and at follow-up. Similar analyses were applied to 
assess the association between mMRCI score and functional status, with initial models assessing 
cross-sectional associations.  ADLs and IADLs were assessed separately. The assumptions of the 
linear regression model were assessed. The residuals of the bivariate analysis between each sub-
score for dosage form or dosage frequency and the main predictors were not normally distributed 
therefore log transformation was applied for the outcome. Finally, the “difficulty taking 
medication” IADL was examined separately in association with complexity in both years. The 
association between mMRCI score and both cognitive and functional impairment at baseline and 
after two years was also examined. Due to low sample sizes in both groups, the analyses could 
not be performed.  
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For the analysis for aim II.3 and III.3 (“Compare factors that contribute to medication 
regimen complexity in participants with and without cognitive impairment at baseline”) survey-
weighted linear regression was used to compare each individual element of the mMRCI between 
individuals with and without cognitive/functional impairments at baseline and after two years.  
The assumptions of the linear regression model were assessed. The residuals of the bivariate 
analysis between each sub-score for dosage form or dosage frequency and the main predictors 
were not normally distributed therefore log transformation was applied for the outcome. 
 For II.4 and III.4, survey-weighted multivariable linear regression was used to examine 
the change in mMRCI (2007 score - 2005 score) and its association with the change in cognitive 
status at baseline as well as its association with the change in functional status (ADL score, and 
IADL score separately). The assumptions of the linear regression model were assessed. Although 
the residuals in the bivariate analysis were normally distributed, there residual vs. predictor plot 
indicated heteroscedasticity, so the main predictors were categorized. 
Change in yes/no covariates such as insurance coverage and history hospital stay were 
assessed by taking the 2007 value and subtracting the 2005 value. The result from the subtraction 
is (0, -1, and 1) which can then be used as a categorical variable. For the predictors ADLs, 
IADLs and cognitive status, changes were created by subtracting across the years, then coding 
the subtracted values into categories (0 = no change, < 0 = score decreased, > 0 = score 
increased). Changes in ordinal variables such as self-rated health were also categorized into no 
change, increase, and decrease. Other continuous variables (income, number of individuals in the 
household, and number of health conditions) were categorized by change status. Change in 
marital status was detected using subtraction, with a value of 0 indicating no change and values 
above or below 0 indicating a change. 
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Other covariates that were unlikely to change over the follow-up period such as gender and years 
of education were represented by using the baseline variable. Additionally, because all 
participants are expected to experience the same increase in age over the two-year follow-up 
period, the baseline variable for age was used. 
1. Sensitivity analyses were performed to determine how the interview types (face to face vs 
telephone) would affect the results. Sensitivity analysis was done by performing the main 
analysis between cognition status and medication complexity at baseline and after two 
years with and without adjusting for the interview type variable and the same was done 
for functional status (ADL and IADL) with medication complexity at baseline and after 
two years. The results showed that after factoring in the interview type, the beta estimates 
of cognition, ADL, and IADL changed by less than 1%. This indicates that the interview 
type has no confounding effect. 
2. Sensitivity analysis was performed, on the same people at baseline and after two years, 
by repeating the multivariable linear analysis of comparing complexity factors in 
participants with and without cognitive/functional impairment (ADL, IADL). The 
analysis was done on two groups and then on three groups (impaired at both timepoints, 
no impairment at both timepoints, and change in impairment between timepoints) and 
since the result produced similar results, it was decided to use only two groups for 
simplicity. 
3. A sensitivity analysis was performed using cognitive decline (defined as score below 20) 
to contrast the result with the results when using cognitive impairment (defined as a score 
below 11). 
4. The 2-way interaction was to test if any disease condition changed the association of 
mMRCI with cognitive/functional impairment. If no 2-way interactions were observed, 
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this would suggest that the other disease conditions did not change the association 
between mMRCI and cognitive or functional impairment. Interactions between cognition, 
ADL and IADL impairments and each disease conditions (cancer, heart disease, lung 
disease, arthritis, psyche, stroke, diabetes, hypertension and depression) were tested at 
baseline and after two years in the multivariable analysis. No significant interactions 
were detected for cognition and ADLs. However, significant interactions were found for 
IADLs and depression, therefore, stratified analysis was performed for IADL analysis by 
depression status. 
5. Multicollinearity was examined among the continuous variables by checking the 
Pearson’s correlation coefficient. Since a high level of correlation was found between 
ADL score and IADL score (r = 0.5, p<0.001) the two variables were kept in separate 
models, and neither variable was used as a covariate when examining the other. All 
statistical analyses were conducted using the SAS statistical software version 9.4 and 
using an alpha cutoff of 0.05.  
3.12 Human Subject Protection and Data Privacy 
The data from the main HRS survey is free and publicly available, however the 
Prescription Drug Study (PDS) is considered sensitive data and requires completing the Sensitive 
Data Access Use Agreement. The study also was reviewed and approved as exempt by the VCU 
IRB.  
3.13 Sample Size of the study  
The starting sample size was 3412 participants. After applying eligibility criteria, 2433 
members of the sample remained, and 979 participants were excluded. After excluding 
individuals who were missing data, 294 individuals were removed, and 2139 participant were 
remained. The exclusion of individuals in 2007 who were found to have reported implausible 
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values for drug frequency, resulting in a final sample size of 2113 participant. The diagram in 
figure 3.1 shows the details of this process.   
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Excluded for missing 
prescription inventory at 
baseline or after two years 
(n=201)  
 2340 participants 
remaining 
Excluded for missing in 
outcome at baseline or after 
two years (n=49)  
2433 participants 
remaining 
Under 65 years old were 
removed (n=700) 
3382 participants 
remaining 
Starting population of 
3412 participants 
Interviewed in nursing 
home were removed (n=30) 
3133 participants 
remaining 
Interviewed by proxy were 
removed (n=249) 
2389 participants 
remaining 
Excluded for missing data 
in main predictors at 
baseline or after two years 
(n=44) 
 2113 participants 
remaining 
2139 participants 
remaining Excluded individuals in 
2007 who were found to 
have reported implausible 
values for drug frequency 
(n=26) 
Figure 1.1 Flow Chart Representing Inclusion and Exclusion for the Final Sample 
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Chapter 4: Results 
 
 
4.1 Characteristics of the Study Sample 
  Of the 2113 eligible participants, 58.75% were between the ages of 65 and 74 years, 
58.37% were female, 90.97% were white, 78.61% had a high school or more advanced level of 
education, 60.70 % were married, and 57.32% earned more than $28,000 per year. A large 
majority (99.37%) were covered by insurance, and 77.19% reported their health was “excellent”, 
“very good” or “good”. Approximately 12.30 % of participants reported having difficulty in 
performing at least one of the ADLs, and approximately 9.80% reported having difficulty in 
performing at least one of the IADLs. Only 1.01% of the sample had cognitive impairment. In 
the 2007 data, the sample was slightly older, and had slightly higher prevalence for cognitive and 
functional impairments and chronic conditions. Demographic characteristics of the study sample 
at baseline and follow-up are summarized in Table 4.1.  The results are weighted to account for 
the complex sample design.
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Table 4.1 Summarizes the Demographic Characteristics of the Study Sample 
Variables  
Total population n=2113 
N, weighted frequency (%) 
(2005) 
 
N, weighted frequency (%) 
(2007) 
Age   
65–74 years 1302 (58.75) 1097 (45.75) 
75–84 years 671 (34.84) 794 (41.84) 
85 years or older 140 (6.40) 222 (12.40) 
Gender   
Male 850 (41.62) 850 (41.62) 
Female 
 
1263 (58.37) 1263 (58.37) 
Marital status   
married 1334 (60.70) 1261 (54.70) 
non-married 778 (39.29) 852 (45.29) 
Race   
White 1822 (90.97) 1822 (90.97) 
Black 229 (6.02) 229 (6.02) 
Other 
 
62 (3.00) 62 (3.00) 
Years of education   
No degree 535 (21.37) 535 (21.37) 
High school 930 (43.90) 930 (43.90) 
Some college 249 (12.95) 249 (12.95) 
College degree 
 
399 (21.76) 399 (21.76) 
Income    
$ 0 to 15999 500 (20.24) 483 (23.24) 
$16000 to 28999 512 (22.43) 511 (22.43) 
$ 29000 to 50999 547 (27.40) 567 (27.40) 
$ 51000 to 134999 445 (23.90) 457 (22.90) 
$ over 135000 
 
109 (6.01) 95 (4.01) 
Covered by insurance   
No 18 (0.62) 17 (0.75) 
Yes  
 
2092 (99.37) 2094 (99.24) 
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Variables  
Total population n=2113 
N, weighted frequency (%) 
(2005) 
 
N, weighted frequency (%) 
(2007) 
Number of people living 
at house 
  
1 563 (28.63) 628 (33.63) 
2-3 1441 (67.20) 1372 (62.20) 
4 or more  
 
109 (4.16) 113 (4.16) 
Previous hospital stay   
No 1492 (71.37) 1441 (67.63) 
Yes 618 (28.62) 669 (32.36) 
Health   
Excellent/very good/good 1581 (77.19) 1525 (70.19) 
Fair 402 (17.59) 439 (21.59) 
Poor 
 
129 (5.20) 144 (8.20) 
ADL    
None  1836 (87.69) 1749 (81.03) 
Impaired 
 
277 (12.30) 364 (18.96) 
IADL    
None  1894 (90.19) 1834 (85.16) 
Impaired 
 
219 (9.80) 279 (14.83) 
Cognitive status   
Cognitive intact 2080 (98.98) 2040 (97.58) 
Impaired 
 
33 (1.01) 46 (2.41) 
Number of conditions   
none 241 (11.40) 178 (8.40) 
1-2 1118 (53.35) 1061 (49.35) 
3-4 659 (30.88) 747 (35.88) 
5 or more 
 
95 (4.35) 127 (6.35) 
Depression    
No  1854 (88.80) 1828 (86.31) 
Yes 
  
259 (11.19) 285 (13.68) 
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4.2 Characterize Medication Complexity among the Population  
Table 4.2 shows the survey-weighted and unweighted median values and interquartile 
ranges for total medication complexity and each of its subscores. The survey-weighted median will 
be presented in the results. The prescription complexity score ranged from 0 to 35, with a median 
of 5.24 and interquartile range (IQR) of 2.65 to 8.98 The number of medications ranged from 0 to 
10 medications. The upper limit of 10 was created because the space provided for participants to 
fill out section “E” in the survey was limited to only 10 medications. Additional medications could 
be listed in a separate file but did not include details such as form and frequency, these 
medications were not counted towards complexity. The median number of medications was 2.86 
(IQR 1.29 to 5.02). The complexity subscore from dosage form ranged from 0 to 14 with a median 
of 0.80 (IQR 0.33 to 1.75).  Lastly, the complexity subscore from dosage frequency ranged from 0 
to 27 with a median of 3.56 (IQR 1.49 to 6.78). All measurements showed small increases in 2007, 
as shown in Table 4.3.  
In Table 4.4, the most common dosage form among the participants was oral medication 
(tables/capsule) with 91.68% of the population taking at least one tablet or capsule. The next most 
common form was inhaled medication, used by 9.02% of the population, followed by other dosage 
forms (ointment, cream, injection, etc.) used by 7.54%, and lastly drops (eyedrops or ear drops) 
used by 5.63%. The most common dosage frequency among the population was once per day with 
87.79% taking at least one medication on this schedule, followed by two times per day with 
47.39% of the population, followed by three times with 10.36% and lastly four times a day with 
9.47% of the population. The prevalence of most dosage frequencies and forms showed small 
increases in 2007, as shown in Table 4.5.  
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Table 4.2 Medication Complexity Sub-Component Scores (2005) 
                       
 
Table 4.3 Medication Complexity Sub-Component Scores (2007) 
 
  
Variables  Score range Weighted median 
(IQR) 
Un-weighted median 
(IQR) 
Medication complexity  0-35 5.24 (2.65 to 8.98) 6.00 (3.00 to 9.00) 
Number of medications  0-10 2.86 (1.29 to 5.02) 3.00 (2.00 to 5.00) 
Dosage form score  0-14 0.80 (0.33 to 1.75) 1.00 (1.00 to 2.00) 
Dosage frequency score  0-27 3.56 (1.49 to 6.78) 4.00 (2.00 to 7.00) 
Variables  Score range Weighted median 
(IQR) 
Un-weighted median 
(IQR) 
Medication complexity  0-35 6.45 (3.39 to 10.61) 7.00 (4.00 to 11.00) 
Number of medications  0-10 3.73 (1.97 to 6.13) 4.00 (2.00 to 6.00) 
Dosage form score  0-18 1.10 (0.46 to 1.95) 2.00 (1.00 to 2.00) 
Dosage frequency score  0-23 4.47 (1.97 to 7.88) 5.00 (2.00 to 8.00) 
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Table 4.4 Percent of People Having Each Dosage Form and Dosage Frequency in 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 Percent of People Having Each Dosage Form and Dosage Frequency in 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dosage form Weighted percentage 
Tablet/ Capsule 91.68% 
Inhalation 9.02% 
Others 7.54% 
Drops 5.63% 
Dosage frequency Weighted percentage 
Once/day 87.79% 
Twice/day 47.39% 
Three/day 10.36% 
Four or more/day 9.47% 
Dosage form Weighted percentage 
Tablet/ Capsule 92.81% 
Inhalation 10.69% 
Others 9.14% 
Drops 5.93% 
Dosage frequency Weighted percentage 
Once/day 88.59% 
Twice/day 46.61% 
Three/day 13.42% 
Four or more/day 9.43% 
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4.3 The Association between Medication Complexity and Cognitive Status at Baseline and 
after Two Years  
The fully-adjusted model at baseline showed that after adjusting for all covariates, for 
every one-unit increase in cognition score, the medication complexity score was 1.02 times higher 
(p<0.0001). This was confirmed by repeating the model after two years: in the 2007 data, it was 
found that after adjusting for all covariates, for every one-unit increase in cognition score, 
complexity increased by a factor of 1.01 (p= 0.0392). (Table 4.6) 
 
          
Table 4.6 Adjusted Association between Cognitive Status and Medication Complexity 
      
 
 
 
 
 
 
 
 
 
 
 
 
  
Variables ß Coefficient* P-value  
At baseline   
Cognitive status  1.02 <0.0001 
After two years    
Cognitive status  1.01 0.0392 
* Due to a violation of the linearity assumption for regression, tests were performed on a log-  
   transformed version of the variable, but results have been exponentiated to return to original values 
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4.4 Compare Factors that Contribute to Medication Complexity in Participants with and 
without Cognitive Impairment at Baseline and after Two Years 
Comparing the complexity factors in those with and without cognitive impairment (defined 
as score below 11) at baseline indicated that there were no statistically significant differences in 
the number of medications score, dosage form score, or dosage frequency score between the two 
groups (p =0.5087), (p=0.9348), and (p=0.9691), respectively. The analysis was repeated after two 
years, and again did not detect any significant differences in the number of medications 
(p=0.4156), dosage form score (p=0.0512), or dosage frequency score (p=0.1687) between the two 
groups. (Table 4.7) 
A sensitivity analysis was performed using cognitive decline (defined as score below 20) to 
contrast this with the results when using cognitive impairment (defined as a score below 11). 
While 1.01% of the sample met the criteria for cognitive impairment, 20.12% of the sample met 
the criteria for cognitive decline. Table 4.6 shows the results of the sensitivity analysis using the 
exposure of cognitive decline. These results indicated that there were significant differences 
between those with cognitive decline and good cognition in number of medications (β =0.90, 
p=0.0037) and dosage frequency scores (β =0.86, p=0.0019) at baseline. After adjusting for all 
covariates, individuals with cognitive decline had lower dosage frequency (β =0.92, p=0.0368) and 
dosage form (β =0.91, p=0.0305), than those who had good cognition, and no significant 
difference in the number of medications between the two groups after two years. (Table 4.8) 
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Table 4.7 Comparison of Complexity Factors in Participants with and  
without Cognitive Impairment 
Variables at baseline  ß Coefficient* p-value 
Number of medications   
Cognitive impairment  0.94 0.5087 
Dosage form   
Cognitive impairment 0.93 0.9348 
Dosage frequency   
 Cognitive impairment 0.99 0.9691 
Variables after two years ß Coefficient* p-value 
Number of medications   
Cognitive impairment 0.95 0.4156 
Dosage form   
Cognitive impairment 0.87 0.0512 
Dosage frequency   
Cognitive impairment 0.86 0.1687 
  * Tests were performed on a log-transformed version of the variable, but results have been  
   exponentiated to return to original values. 
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Table 4.8 Comparison of Complexity Factors in Participants with and  
without Cognitive Decline 
Variables at baseline ß Coefficient* p-value 
Number of medications   
Cognitive impairment 0.90 0.0037 
Dosage form   
Cognitive impairment 0.95 0.1585 
Dosage frequency   
Cognitive impairment 0.86 0.0019 
Variables after two years  ß Coefficient* p-value 
Number of medications   
Cognitive impairment 0.92 0.1902 
Dosage form   
Cognitive impairment 0.91 0.0305 
Dosage frequency   
Cognitive impairment 0.92 0.0368 
 
  
* Tests were performed on a log-transformed version of the variable, but results have been  
   exponentiated to return to original values. 
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4.5 The Association between Medication Complexity and Functional (ADL and IADL) Status 
at Baseline and after Two Years  
 
ADL Impairments 
At baseline, adjusted comparison of complexity score and ADL score showed that after adjusting 
for all covariates, for one-unit increase in ADL score, medication complexity was 1.06 times 
higher (p=0.0029). This association remained significant after two years (p=0.0243). (Table 4.9)  
 
 
 
Table 4.9 Adjusted Association between ADL Functional Status  
and Medication Complexity 
 
 
 
 
 
 
 
 
 
 
  
Variables  ß Coefficient* p-value 
ADL at baseline    
Functional status  1.06 0.0029 
 ADL after two years    
Functional status  1.04 0.0243 
 
* Tests were performed on a log-transformed version of the variable, but results have been  
   exponentiated to return to original values. 
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IADL Impairments 
At baseline, there was significant association between IADL score and medication complexity. For 
one-unit increase in IADL score, complexity was 1.07 times higher (p=0.0130). This association 
did not remain significant after two years (p=0.2412). (Table 4.10) 
Interactions between number of IADL impairments and each disease participant have been tested 
at baseline and after two years. Significant interactions were detected between depression and 
IADL score at both baseline and follow-up. Due to this interaction, the analyses were repeated 
using stratification by depression status. (Table 4.11) 
For participants without depression, at baseline after adjusting for all covariates, for one-unit 
increase in IADL score, medication complexity was 1.14 times higher (p=0.0001) and for 
participants with depression, no significant association between IADL score and complexity score 
was detected at baseline (p=0.4679). After two years, for participants without depression, after 
adjusting for all covariates, for one-unit increase in IADL score, medication complexity was 1.05 
times higher (p=0.0334) and for participants with depression, no significant association between 
IADL score and complexity score was detected (p=0.4003). (Table 4.11).  
The number of individual who reported having difficulty taking medication in the IADL 
measure was 26. In addition to that, the number of individuals with both cognitive impairment and 
ADL impairment (n = 8) and both cognitive impairment and IADL impairment (n = 12) were too 
low to provide adequate power for statistical testing, so individuals with difficulty taking 
medication and multiple categories of impairment could not be analyzed as a separate group. 
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Table 4.10 Association between IADL Functional Status and Medication Complexity 
 Variables  ß Coefficient* p-value 
IADL (unstratified) analysis at baseline    
Functional status 1.07 0.0130 
IADL (unstratified) analysis at after two years    
Functional status 1.02 0.2412 
 
 
 
 
Table 4.11 Association between IADL Functional Status and Medication 
Complexity, Stratified by Depression 
Variables  
Not depressed 
ß Coefficient* 
p-value 
Depressed 
ß Coefficient * 
p-value 
IADLs at baseline 1.14  
 
0.0001  0.97  
 
0.4679 
IADLs after two years 1.05  
 
0.0334    0.96  
 
0.4003 
 
 
  
 
* Tests were performed on a log-transformed version of the variable, but results have been exponentiated  
   to return to original values 
 
 
* Tests were performed on a log-transformed version of the variable, but results have been exponentiated   
   to return to original values. 
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4.6 Compare Factors that Contribute to Medication Complexity in Participants with and 
without Functional Impairment (ADL and IADL) at Baseline and after Two Years  
 
ADL Impairments 
There was a significant difference in the number of medications and dosage frequency 
between the ADL-impaired and the ADL-unimpaired groups. After adjusting for all covariates, 
ADL functional impairment was associated with a higher number of medications (β =1.13, 
p=<.0001) and a higher dosage frequency (β =1.14, p=0.0005) compared to those without ADL 
impairment. There was no significant difference in the dosage form score between the two groups 
at baseline (p=0.9174). These results were repeated after two years, and results showed the same. 
After adjusting for all covariates, individual who have ADL impairment are associated with higher 
number of medications and higher dosage frequency than those without ADL impairment (β =1.09, 
p=0.0170), (β =1.07, p=0.0431) respectively. (Table 4.12)  
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Table 4.12  Comparison of Complexity Factors in Participants with and without  
Functional Impairment in ADLs 
 
 
  
Variables at baseline  ß Coefficient* p-value 
Number of medications   
Functional impairment 1.13 <0.0001 
Dosage form   
Functional impairment 1.00 0.9174 
Dosage frequency   
Functional impairment  1.14 
0.0005 
 
Variables after two years ß Coefficient* p-value 
Number of medications   
Functional impairment 1.09 0.0170 
Dosage form   
Functional impairment  1.02 0.3294 
Dosage frequency   
Functional impairment  1.07 0.0431 
 
* Tests were performed on a log-transformed version of the variable, but results have been   
   exponentiated to return to original values. 
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IADL Impairments 
There was a significant difference in the number of medications and dosage frequency 
between the IADL-impaired and IADL-unimpaired groups. After adjusting for all covariates, 
IADL functional impairment was associated with higher number of medications (β =1.17, 
p=0.0017) and a higher dosage frequency score (β =1.23, p=0.0002) compared to those without 
IADL impairment. There was no significant difference in the dosage form score between the two 
groups at baseline (p=0.1505). These results were repeated after two years, results showed that no 
significant difference was found for number of medications, dosage form and dosage frequency 
between the two groups (Table 4.13). 
IADL Impairments Stratified by Depression  
After adjusting for all covariates, individuals with IADL impairment and who were not 
depressed had significantly higher numbers of medications than individuals without impairments 
(β=1.24, p=0.0002). Individuals with IADL impairments also had significantly higher scores for 
dosage frequency (β=1.32, p <.0001) and dosage form (β=1.12, p= 0.0366) at baseline. These 
differences remained significant only for number of medications but not for dosage form and 
dosage frequency after two years. Those with IADL impairment and not depressed had higher 
number of medication (β =1.13, p=0.0426) than those without IADL impairment. Among 
individuals with depression, those with and without IADL impairments did not differ in number of 
medications, dosage form score, or dosage frequency score. This result was the same at baseline 
and after two years. (Table 4.14).  
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Table 4.13 Comparison of Complexity Factors in Participants with and without  
Functional Impairment in IADLs 
 
 
  
Variables at baseline  ß Coefficient* p-value 
Number of medications   
Functional impairment 1.17 0.0017 
Dosage form   
Functional impairment 1.07 0.1505 
Dosage frequency   
Functional impairment 1.23 
0.0002 
 
Variables after two years ß Coefficient* p-value 
Number of medications   
Functional impairment 1.03 0.4267 
Dosage form   
Functional impairment 1.05 0.2146 
Dosage frequency   
Functional impairment 1.04 0.3568 
* Tests were performed on a log-transformed version of the variable, but results have been exponentiated  
    to return to original values. 
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Table 4.14 Comparison of Complexity Factors in Participants with and without 
Functional Impairment in IADLs 
 
  
Variables at baseline 
Not depressed 
ß Coefficient* 
p-value 
Depressed 
ß Coefficient* 
p-value 
Number of medications     
Functional impairment 1.24 0.0002 1.00 0.9573 
Dosage form     
Functional impairment 1.12 0.0366 0.96 0.6458 
Dosage frequency     
Functional impairment 1.32 <.0001 1.01 0.9310 
Variables after two years 
Not depressed 
ß Coefficient* 
p-value 
Depressed 
ß Coefficient* 
p-value 
Number of medications     
Functional impairment 1.13 0.0426 0.92 0.3277 
Dosage form     
Functional impairment 1.06 0.2145 1.03 0.6464 
Dosage frequency     
Functional impairment 1.10 0.0899 0.89 0.1806 
* Tests were performed on a log-transformed version of the variable, but results have been exponentiated  
   to return to original values. 
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4.7 Assess the Change in Medication Regimen Complexity Score and its Association with 
Change in Cognitive and Functional Status over Two Years  
The analysis of the association between the change in mMRCI score and the change in each 
of the main predictors (ADL status, IADL status, and cognitive status) showed that there were no 
significant differences in the changes in mMRCI score after two years. (Table 4.15) 
 
Table 4.15 Association Between Change in Predictors and Changes 
 in Medication Complexity 
Variables ß Coefficient p-value 
Cognitive status   
No change Ref Ref 
Cognitive declined  -0.19 0.5068 
Cognitive improved  0.01 0.9956 
Functional status (ADL)   
No change  Ref Ref 
Functional declined  0.19 0.7579 
Functional improved  0.24 0.6003 
Functional status (IADL)   
No change Ref Ref 
Functional declined  0.67 0.3166 
Functional improved  0.57 0.2614 
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4.8 Summery 
These results support the existence of a relationship between good cognition and 
complexity, with cognitive impairment associated with lower medication regimen complexity. The 
decreased complexity was primarily due to the less complicated dosage forms and dosage 
frequencies prescribed to these individuals. ADL impairment shows more robust association with 
the increasing of medication regimen complexity than IADL impairment. ADL impairment was 
associated with higher medication regimen complexity at both baseline and after two years, with 
the number of medications and dosage frequency showing similar increases. The association 
between IADL and medication regimen complexity needs further investigation. Stratifying by 
depression status, IADL impairment was found to predict higher complexity in participants 
without depression but not participants with depression. There was no significant relationship 
between changes in cognitive/functional status and changes in medication regimen complexity 
over two years, however there is a need to continue to assess these changes over a longer period of 
time. 
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Chapter 5: Discussion 
 
5.1 The Relationship between Cognitive Status and Medication Regimen Complexity 
Higher cognitive scores were associated with higher medication regimen complexity, and 
lower cognitive scores were associated with lower complexity. This association could be the result 
of prescribers stopping or decreasing medications for cognitively impaired patients in 
consideration of the disease trajectory, treatment care goals, and life expectancy of the patients.133 
The observed decrease in medication complexity was present regardless of the type of chronic 
disease affecting the patient.  This might reflect a switch from potentially curative therapy intended 
to prolong the patient’s life to palliative treatment intended to provide symptomatic relief while 
reducing the adverse effects from medication.134 Furthermore, the deterioration of the cognitive 
function might lead the physicians to reassess the patient’s medication regimen which leads to 
reductions in medication regimen complexity.133 Patients or care providers may also request that 
physicians prescribe a simpler regimen in response to subclinical or overt cognitive impairment. 
This is consistent with a previous study by Lee et al. which reported that cognitive impairment was 
inversely associated with medication regimen complexity and suggested that clinicians may have 
made the regimens less complicated in order to make it more convenient for the patients to manage 
their medications.35 This is also consistent with the results of Wimmer et al. who found that 
patients with more complex regimens had higher cognitive scores than patients with less complex 
regimens.36 
The attributable reason of why cognitive impairment was associated with lower complexity 
was further investigated. Using a cutoff score of 11 to define cognitive impairment135’131, the 
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cognitively impaired group did have fewer medications and less complex dosage forms and dosage 
frequencies, but these differences were not statistically significant. The results may not have 
reached significance because only a very small proportion of the sample (1.01%) had a cognitive 
score below the cutoff.  Sensitivity analysis using a higher cutoff of 20 to represent cognitive 
decline,136 resulted in 20.12% of the sample being classified as having lower cognitive 
performance. With this definition, the results showed that at baseline those with cognitive decline 
had significantly lower number of medication and less dosage frequencies.   
After two years still, those with cognitive decline had less dosage frequencies in addition to 
less complex dosage forms. However, number of medication no longer become significant with the 
higher cognitive score cutoff; there were no differences in the number of medications between the 
cognitive decline and normal cognitive function groups after two years. This is consistent with the 
results of Lee et al. who found no difference in number of medications between groups, and who 
suggested that the differences in complexity could result from other factors such as form and 
frequency.35 
5.2 The Relationship between Functional Status and Medication Regimen Complexity 
Higher ADL scores (which indicate greater functional impairment) were associated with higher 
medication regimen complexity at baseline and after two years. This was consistent with the 
results of Herson et al.34 who found that independence in activities of daily living (ADLs) was 
associated with low regimen complexity. Our results indicated that the higher medication regimen 
complexity in the functionally impaired group was attributable to significantly higher numbers of 
prescriptions, as well as higher dosage frequencies. Many chronic conditions require treatment, 
thus multiple comorbidities are associated with higher medication regimen complexity.36 
Depending on the severity of the conditions, patients may have increased number of medications, 
dosage forms, and frequencies of intake. Chronic conditions may also lead to difficulties in 
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walking, standing, and fine motor skills, contributing to functional impairment.137 However, no 
interactions were found between functional impairment and specific chronic conditions, indicating 
that functional impairment was associated with increased complexity regardless of which specific 
chronic conditions were present.  
The findings from this study show that ADL functional impairment scores can serve as a 
predictor of medication regimen complexity, which suggests that there are opportunities for health 
care providers to intervene by re-assessing medication regimens for functionally impaired patients. 
Complex medication regimes have been linked with poor adherence.25‘
27 Functional impairment is 
also known to reduce compliance with medication regimens.105’
106 These results indicate that more 
effort is required to reduce medication regimen complexity in geriatric patients with impaired 
ADLs. 
Although there was an association between ADL impairment and complexity, there was no 
clear association between IADL impairment and medication complexity. The association was 
significant at baseline but not after two years. Therefore, this association requires further 
investigation. One way to interpret the results would be to look at the relationship between IADL 
and cognitive impairment. The high correlation between cognitive decline and a decline in the 
ability to perform IADLs has been shown in previous studies.138’139 IADLs require more complex 
neuropsychological processing capacity than ADLs and therefore are more prone to deterioration 
triggered by cognitive decline.140’141 In particular, a decline in executive function can be a key 
contributor to impairment in IADLs.138 Functional deficits have been observed early in the course 
of cognitive decline.142’143 Nygård et al. reported that IADLs can be impaired before the onset of 
dementia, and should therefore be included in the diagnosis of mild cognitive impairment.144 
Therefore, we could assume that doctors tend to reduce the medication complexity for their 
patients based on their cognitive function. Meanwhile, the functional status of the patients is often 
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not investigated as much. Establishing a baseline of cognitive function and functional status is not 
the current standard of practice. The functional and cognitive status of patients has been shown to 
correlate well with multiple outcomes such as their length of hospitalization, recovery and their 
ability to carry out their activities post recovery. In order to have better data to assess the 
relationship between functional status IADLs and medication regimen complexity, we must 
promote their assessment as the standard of care in various medical settings.145  
When stratifying by depression status, the result showed that IADL impairment was 
significantly associated with higher medication regimen complexity only in the strata of 
individuals without depression, and that there was no significant association between IADL 
impairment and medication regimen complexity for individuals with depression. The lack of a 
significant result in the depression strata could have been due to the relatively small sample size of 
this strata (259 people) which may have reduced statistical power, however the interaction term 
between IADL impairment and depression status was significant in the unstratified model which 
suggests that there may be a true underlying difference. 
Although depression treatment may lead to increases in medication regimen complexity35, 
individuals with depression often do not seek help or receive treatment. Individuals with 
depression are also more likely to neglect their health, less likely to seek medical advice, and more 
likely to forget to take their medications or even pick them up.146 Depression may be a barrier to 
adherence with a complicated medication regimen, with patients who are depressed being less 
likely to take their medications as prescribed.147 It has been reported that there is a threefold 
increase in the odds of non-compliance among individuals with depression.148 As such, this lack of 
significance could be explained by the fact that even if these individuals should have had a high 
number of medications, they may not have sought help or been compliant with their medication 
regimens, leading to lower medication use and therefore lower reported complexity. 
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5.3 The Relationship between Changes in Cognitive/Functional Status and Changes in the 
Medication Regimen Complexity 
There were no significant associations between changes in cognitive impairment, ADL 
impairment, or IADL impairment and changes in complexity over two years.  In an aging 
population, there are some characteristics like cognition, functional ability, and medication 
complexity that are expected to change over time. Cognition and function will likely decline, due 
in part to the natural process of aging.149 Similarly, as older adults  age they face more health 
issues, that often require them to take multiple medications to treat chronic health problems and, 
based on that, the nature of medication complexity will also change becoming more 
complex.10’11’12 These changes may take years to manifest, and the ages at which they occur may 
differ between individuals based on genetics, lifestyle, and prior medical history.150 Rates of 
decline may become more rapid in the later stages of disease, which may not be captured with only 
two years of follow-up.151 Another important factor to consider is hospitalization, which is 
associated with greater changes in cognitive and functional impairment and with increases in 
complexity.152  Only 28.6% of our sample reported hospitalization during the two years of follow 
up, which may have limited our ability to detect hospitalization-related changes.   
Descriptive analysis found that the majority of the sample (58.75%) was in the youngest 
age group of 65-74 years old. Most of the sample (98.98%) had good cognition, and the prevalence 
of ADL impairments and IADL impairments was low (12.30% and 9.80% respectively). 77.19% 
of participants reported that their health was excellent, very good, or good. The prevalence of most 
chronic conditions was low, with the exceptions of hypertension (66.52%) and arthritis (62.83%). 
These results indicate that participants in the Prescription Drug Study were a fairly healthy sample. 
The prevalence of most chronic conditions, and the prevalence of ADL and IADL impairments, 
did not differ between the PDS sample and the overall HRS sample. 
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For comparison, the sample used in this study was compared to a more recent HRS sample 
from 2012. Similar to the PDS, the majority of the HRS 2012 participants (57.12%) were in the 
youngest age group (65 to 74 years old). The majority of the sample had good cognition (96.55%), 
15.02% reported IADL impairments, and 16.84% reported ADL impairment. As in the PDS 
sample, the prevalence of most of the chronic conditions was low, with the exceptions of 
hypertension (68.34%) and arthritis (68.94%). 73.13% of participants reported that their health was 
excellent, very good, or good. Details of the 2012 comparison sample can be found in appendix B. 
Over the two years of follow-up, the PDS sample did not experience large changes in the 
prevalence of cognitive impairment (1.01% vs. 2.41%), IADL impairment (9.80% vs. 14.83%), or 
ADL impairment (12.30% vs. 18.90%). This may also help to explain why no significant 
relationship was detected between changes in these predictors and changes in complexity between 
the two periods. 
5.4 Strengths and Limitations  
Results should be interpreted in light of the strengths and limitations of this study. 
Although the data was longitudinal, only two years of follow-up were available in the PDS, so any 
changes occurring beyond these two years were not captured. Although a longer follow-up period 
would be desirable this data is not currently available. PDS data was not captured at the same time 
as the primary HRS survey data, thus it is possible that undetected changes between times of 
measurement may influence results (for example, an individual with low impairment in the 2004 
HRS survey may have suffered a stroke and experienced increased impairment before the 2005 
PDS survey). Because the HRS used both telephone and face-to-face interview modes, and only a 
subset of cognitive tests could be performed during the telephone interviews, it was not possible to 
measure all aspects of cognitive function such as executive function. 
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As with all survey data, bias affecting self-reported answers cannot be eliminated. The 
medication inventory is completed by the participants as part of a mail-in survey or telephone 
interview. Cognitive impairment may have impacted the reporting of medication because people 
with cognitive impairment may be less able to provide accurate medication information, creating 
recall bias. It was possible to check for certain types of missing information. The impaired and 
unimpaired groups did not show large differences in the percent of individuals leaving the 
prescription inventory section blank (5.7% and 6.4%, respectively). The percent of individuals 
who omitted frequency or format details for at least one prescriptions also did not show large 
differences (29.8% in those without cognitive impairment, and 28.7% in those with cognitive 
impairment). Other missing information could not be checked, such as individuals leaving 
prescriptions out of the inventory or providing inaccurate details, so it is still possible that this 
could have contributed to bias. The measures used in HRS to assess functional status are also 
based on self-report of participants’ functional status at the time of interview and may not capture 
fluctuations in functional status over time unless they are substantial. 
Although the PDS survey asked participants to report their over the counter medications in 
a separate section, this section did not include any details about dosage form and dosage 
frequency, so only prescription medications were considered when calculating the complexity 
score. Individuals with partially missing prescription details were included in the study, which 
likely led to lower complexity scores for these participants as the missing data could not count 
towards their complexity scores. Although the low scores for these individuals are not ideal, 
including these individuals in the sample was still preferable, because omitting them would have 
excluded a large proportion of the sample and would also have led to biased and non-
representative sample. The detailed drug report section allowed a maximum of 10 prescriptions, so 
individuals with more than 10 prescriptions could not report all their medications and would also 
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have received lower complexity scores. Of the 2113 participants, only 54 people (2.6%) at baseline 
and 83 people (3.9%) at follow-up responded to the question “How many medications do you take 
regularly?” with a number greater than 10. This means that most of the sample would have been 
able to report all of their medications in the prescription inventory, which reduces the potential 
impact of this limitation. Finally, because the PDS data lacked information about additional 
directions included with the prescription, the complexity measurement instrument used in this 
study was a modified scale that did not account for this dimension of complexity, leading to a 
lower total complexity score. Although this reduces comparability with other studies that used the 
full instrument, the modified instrument has also been used in other studies, so it is possible to 
compare the results of this study with some existing literature. (cite) Additionally, existing 
literature using the full complexity instrument has reported that form and frequency are the two 
components with the greatest effect on complexity, and these two factors are included in the 
modified instrument.  
It was not possible to perform analysis of individuals with both functional and cognitive 
impairment due to small sample sizes (8 people had both cognitive and ADL impairments, and 12 
people had both cognitive and IADL impairments). The criteria excluding those interviewed by 
proxy at baseline (7.3% of the population) is likely to have led to underrepresentation of those with 
the most severe cognitive or functional impairments and may also have led to underrepresentation 
of individuals with both cognitive and functional impairment. However, the purpose of this study 
was to examine complexity among people who were able to care for themselves and were likely to 
be managing their own medications, and such individuals would be unlikely to be interviewed by 
proxy, so the exclusion criteria were consistent with the study intentions. However, future studies 
examining complexity in more severely impaired individuals are recommended. 
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Due to the data usage agreement with the HRS, it was not possible to share the prescription 
details with others. With only one person coding the prescriptions, it was not possible to test inter-
rater reliability. However, the differences between prescription complexity in 2005 (where 
prescription details were coded by hand) and 2007 (where the majority of prescription details were 
coded by HRS staff) were not large and were in the expected direction (as study participants got 
older, their complexity was expected to increase) which suggests that the hand-coded details were 
fairly consistent with the HRS-coded details. 
The PDS data was collected in 2005 and 2007, and it is possible that there may have been 
some changes in clinical and prescribing practices since then. However, recent literature suggests 
that the need to assess for cognitive and functional impairments in clinical settings is still an 
important issue, which would suggest that practitioners are still often not accounting for these 
factors. Thus, although this study uses older data, it still contributes important information to 
support the need for prescribers to assess impairment and review medication complexity to 
improve adherence in older adults. 
This study also had several strengths, including the use of a complexity score that reflected 
multiple dimension of complexity (number of medications, dosage form, and dosage frequency), 
the use of longitudinal data, and the availability of detailed covariates that allowed for thorough 
assessment of confounding. This study also assessed ADL, IADL, and cognitive impairment in 
tandem in the same sample, and was the first study to do so using longitudinal data from a 
nationally-representative sample. Another strength of this study was that interactions were 
examined between chronic conditions and each of the main predictors, which confirmed that the 
associations between impairment and complexity were robust across a variety of conditions.  
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5.5 Implications and Future Directions  
The results of this study have three main implications for clinical practice. First, regular 
assessment of cognitive and functional impairments should be a standard of care for older adults. 
Second, it is important to review medications to identify complex regimens that increase risk of 
poor adherence. Finally, it is important to combine this information to identify individuals with 
impairments and complex medication regimens who may be particularly in need of interventions to 
reduce their regimen complexity while still meeting their medical needs.  
To facilitate these recommendations, it will be important to have an interconnected system 
to manage information from all of a patient’s healthcare providers, so doctors can be aware of all 
of their patients’ prescriptions from different sources and be able to account for this in their own 
prescribing and to communicate any concerns to the patient’s other providers. Doctors should also 
routinely assess for cognitive and functional impairment that may indicate a particularly strong 
need to reduce a patient’s prescription complexity. Some programs, such as Medicare, have 
implemented a requirement for assessment of cognitive impairment as part of an annual wellness 
appointment, however more frequent assessments including both cognitive and functional 
impairment should become a routine standard of care. 
The findings of this study can play a significant role in encouraging further research in this 
area. Although this is an observational study that cannot demonstrate causation, it does provide 
evidence of an association between complexity and impairment. Existing studies have shown that 
individuals with impairment are at higher risk poor adherence, and that higher complexity is also a 
risk factor for poor adherence. Based on this information, it seems reasonable to suggest an 
intervention study to assess whether reducing complexity for those with cognitive/functional 
impairment would improve their adherence. The intervention study could also include individuals 
without impairments, to see if the intervention has a greater impact for individuals with 
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impairments, especially individuals with functional impairments who are likely to have higher 
complexity. Also, more studies are needed to assess the association between cognitive/functional 
impairment and medication complexity over longer periods of time, particularly to clarify the 
relationship between IADL impairment and complexity. Further research is also needed to 
investigate how changes in cognitive/functional status would predict changes in medication 
complexity over longer periods of time. This would help determine how the changes in functional 
status would predict the changes in MRCI.  Also, it would be interesting to include all 
prescriptions and over the counter medications in the study to determine which has the greatest 
effect on complexity. We were not able to determine this in our study because of the nature of 
HRS data that only captures full details for prescription medication.  
5.6 Conclusion 
This population-based retrospective longitudinal study was conducted to understand the 
cross-sectional associations between cognitive status, functional status and medication regimen 
complexity among older adults, and to examine how changes in these factors would predict the 
changes in medication regimen complexity over a period of two years. The analysis found that 
ADL impairment was a key predictor of higher medication regimen complexity but IADL 
impairment association with medication complexity needed further investigation. Cognitive 
impairment was associated with lower medication regimen complexity. None of the changes in 
these factors were predictors of change in medication regimen complexity over two years. 
Suggestions for future research in this area include 1) investigating the relationship between IADL 
impairment and medication regimen complexity among older adults, 2)  studying the association 
between the change in cognitive/functional status and the change in medication regimen 
complexity over longer period of time,  3) studying the effect of medication regimen complexity 
on adherence of those with and without cognitive/functional impairment and 4) whether functional 
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status assessment in clinical practice would result in reduced medication complexity and therefore 
improved medication adherence. 
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The Medication Regimen Complexity Index, Sections B and C (George et al., 2004, p. 1375) 
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Appendix B 
 
Table 4.1 Summarizes the Demographic Characteristics of the Study Sample at 2012 
     
Variables  
Total population n= 9694 
N, weighted frequency (%) 
 
 
Age  
65–74 years 4834 (57.06) 
75–84 years 3724 (31.47) 
85 years or older 
 
1136 (11.46) 
Gender  
Male 4026 (43.02) 
Female 
 
5668 (56.97) 
Marital status  
married 5799 (58.81) 
non-married 
 
3893 (41.18) 
Race  
White 7977 (87.47) 
Black 1324 (8.58) 
Other 
 
389 (3.94) 
Years of education  
No degree 2189 (19.63) 
High school 4060 (41.52) 
Some college 1353 (14.40) 
College degree 
 
2085 (24.43) 
Income   
$ 0 to 15999 1810 (17.26) 
$16000 to 28999 2051 (19.46) 
$ 29000 to 50999 2628 (26.31) 
$ 51000 to 134999 2584 (28.98) 
$ over 135000 
 
621 (7.96) 
Number of people living at house  
1 2747 (31.18) 
2-3 6219 (62.11) 
4 or more  
 
728 (6.69) 
Covered by insurance  
No 0 (0) 
Yes  
 
9512 (100) 
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Previous hospital stay  
No 6697 (70.02) 
Yes 
 
2943 (29.97) 
Health  
excellent/very good/good 6917 (73.13) 
fair 2031 (19.78) 
Poor 
 
733 (7.07) 
ADL   
None  7958 (83.15) 
Impaired 
 
1728 (16.84) 
IADL   
None  8129 (84.97) 
Impaired 
 
1557 (15.02) 
Difficulty taking medication   
No  9271 (97.19) 
Yes  
 
291 (2.67) 
Cognitive status  
Cognitive intact 9301 (96.55) 
Impaired 
 
393 (3.44) 
Cognitive and ADL  
No 9538 (98.67) 
Yes  
 
156 (1.32) 
Cognitive and IADL  
No 9500 (98.25) 
Yes 
 
194 (1.74) 
Number of conditions  
none 557 (6.56) 
1-2 4294 (45.59) 
3-4 3893 (38.60) 
5 or more 
 
945 (9.23) 
Hypertension  
No 2798 (31.65) 
Yes 
 
6744 (68.34) 
Heart disease  
No 6509 (68.39) 
Yes 
 
3168 (31.60) 
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Lung disease  
No 8465 (87.70) 
Yes 
 
1215 (12.29) 
Arthritis  
No 2863 (31.05) 
Yes 
  
6817 (68.94) 
Stroke  
No 8598 (89.53) 
Yes 
 
1084 (10.46) 
Depression   
No  8418 (87.52) 
Yes 
  
1276 (12.47) 
Cancer   
No 7637 (79.36) 
Yes 
 
2023 (20.63) 
Psyche  
No 8061 (82.46) 
Yes 
 
1618 (17.53) 
Diabetes  
No 7345 (83.38) 
Yes 1641 (16.61) 
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